International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 73

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in *Cumulative List No. 15, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 73

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la *Liste récapitulative No. 15, 2013* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 73

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran reunidas en *Cumulative List No. 15, 2013* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

abrilumabum #	
abrilumab	immunoglobulin G2-kappa, anti-[*Homo sapiens* integrin ITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin α4β7, lymphocyte Peyer's patch adhesion molecule 1, LPAM-1)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-444) [*Homo sapiens* VH(IGHV1-24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) -IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide
abrilumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* intégrine ITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine α4β7, récepteur d'adressage spécifique des plaques de Peyer, LPAM-1)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-444) [*Homo sapiens* (IGHV1-24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) -IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère(220-220":221-221":224-224":227-227")-tétrakisdisulfure
abrilumab	inmunoglobulina G2-kappa, anti-[*Homo sapiens* integrina ITGA4_ITGB7 (integrina alfa4 (CD49d)_beta7, integrina α4β7, molécula de adhesión específica de linfocitos de las placas de Peyer, LPAM-1)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-444) [*Homo sapiens* (IGHV1-24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) -IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero(220-220":221-221":224-224":227-227")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKVSGYTLS DLSIHWVRQA PGKGLEWMGG  50
FDPQDGETIY AQKFQGRVTM TEDTSTDTAY MELSSLKSED TAVYYCATGS 100
SSSWFDPWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG  50
ASNLESGVPS RFSGSGSGTD FTLTISSLQP EDFANYYCQQ ANSFPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	258-318	364-422
	22"-96"	145"-201"	258"-318"	364"-422"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	132-214'	132"-214'"		
Inter-H-H (h 4, h 5, h 8, h 11)	220-220"	221-221"	224-224"	227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"

acorafloxacinum

acorafloxacin — 7-[(3*E*)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

acorafloxacine — acide 7-[(3*E*)-3-(2-amino-1-fluoroéthylidène)pipéridin-1-yl]-1-cyclopropyl-6-fluoro-8-méthoxy-4-oxo-1,4-dihydroquinoléine-3-carboxylique

acorafloxacino — ácido 7-[(3*E*)-3-(2-amino-1-fluoroetilideno)piperidin-1-il]-1-ciclopropil-6-fluoro-8-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico

$C_{21}H_{23}F_2N_3O_4$



acumapimodum

acumapimod — 3-[5-amino-4-(3-cyanobenzoyl)-1*H*-pyrazol-1-yl]-*N*-cyclopropyl-4-methylbenzamide

acumapimod — 3-[5-amino-4-(3-cyanobenzoyl)-1*H*-pyrazol-1-yl]-*N*-cyclopropyl-4-méthylbenzamide

acumapimod — 3-[5-amino-4-(3-cianobenzoil)-1*H*-pirazol-1-il]-*N*-ciclopropil-4-metilbenzamida

$C_{22}H_{19}N_5O_2$



albenatidum #

albenatide

S$^{3.34}$-{1-[(23*S*)-23-{[exendin-4 *Heloderma suspectum* precursor-(48-86)-peptidyl (exenatidyl)]amino}-3,12,24-trioxo-7,10-dioxa-4,13,18,25-tetraazapentacosyl]-2,5-dioxopyrrolidin-3-yl}human serum albumin.
Peptide is synthetic, and human serum albumin is produced in *Saccharomyces cerevisiae*.

albénatide

S$^{3.34}$-{1-[(23*S*)-23-{[précurseur de l'exendin-4 de *Heloderma suspectum*-(48-86)-peptidyl (exénatidyl)]amino}-3,12,24-trioxo-7,10-dioxa-4,13,18,25-tétraazapentacosyl]-2,5-dioxopyrrolidin-3-yl}albumine sérique humaine.
Le peptide est synthétique et l'albumine sérique humaine est produite par *Saccharomyces cerevisiae*.

albenatida

S$^{3.34}$-{1-[(23*S*)-23-{[precursor de la exendina-4 de *Heloderma suspectum*-(48-86)-peptidil (exenatidil)]amino}-3,12,24-trioxo-7,10-dioxa-4,13,18,25-tetraazapentacosil]-2,5-dioxopirrolidin-3-il}albúmina sérica humana.
El péptido es sintético y la albúmina sérica humana la produce el *Saccharomyces cerevisiae.*

Human Albumin / Albumine humaine / Albumina humana

```
DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 50
KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE 100
CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 200
ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 250
LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 300
DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA 350
KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE 450
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL                 585
```

Exenatidyl / Exénatidyl / Exenatidil

```
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS-            39
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
53-62 75-91 90-101 124-169 168-177 200-246 245-253 265-279 278-289
316-361 360-369 392-438 437-448 461-477 476-487 514-559 558-567

Modified residues / Résidus modifiés / Restos modificados



asvasiranum

asvasiran

small interfering ARN (siRNA) inhibitor of human Respiratory Syncytial Virus replication;
duplex of guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine and thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidine

asvasiran

petit ARN interférant (siRNA) inhibiteur de la réplication du virus respiratoire syncytial humain;
duplex de guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine et de thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidine

asvasirán

ARN pequeño de interferencia (ARNip) (siRNA) inhibidor de la replicación del virus respiratorio sincitial humano;
duplex de guanilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-timidina y de timidilil-(5'→3')-timidilil-(5'→3')-citidilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidina

$C_{401}H_{500}N_{150}O_{290}P_{40}$

```
[(3'-5')-G-G-C-U-C-U-U-A-G-C-A-A-A-G-U-C-A-A-G-dT-dT]
         . . . . . . . . . . . . . . . . . . . .
[(5'-3')-dT-dT-C-C-G-A-G-A-A-U-C-G-U-U-U-C-A-G-U-U-C]
```

azeliragonum

azeliragon — 3-(4-{2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1*H*-imidazol-4-yl}phenoxy)-*N,N*-diethylpropan-1-amine

azéliragon — 3-(4-{2-butyl-1-[4-(4-chlorophénoxy)phényl]-1*H*-imidazol-4-yl}phénoxy)-*N,N*-diéthylpropan-1-amine

azeliragón — 3-(4-{2-butil-1-[4-(4-clorofenoxi)fenil]-1*H*-imidazol-4-il}fenoxi)-*N,N*-dietilpropan-1-amina

$C_{32}H_{38}ClN_3O_2$



basmisanilum

basmisanil — (1,1-dioxo-1λ^6-thiomorpholin-4-yl)(6-{[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy}pyridin-3-yl)methanone

basmisanil — (1,1-dioxo-1λ^6-thiomorpholin-4-yl)(6-{[3-(4-fluorophényl)-5-méthyl-1,2-oxazol-4-yl]méthoxy}pyridin-3-yl)méthanone

basmisanil — (1,1-dioxo-1λ^6-tiomorfolin-4-il)(6-{[3-(4-fluorofenil)-5-metil-1,2-oxazol-4-il]metoxi}piridin-3-il)metanona

$C_{21}H_{20}FN_3O_5S$



beclabuvirum

beclabuvir — (4b*S*,5a*R*)-12-cyclohexyl-*N*-(dimethylsulfamoyl)-3-methoxy-5a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4b,5,5a,6-tetrahydrocyclopropa[*d*]indolo[2,1-*a*][2]benzazepine-9-carboxamide

béclabuvir — (4b*S*,5a*R*)-12-cyclohexyl-*N*-(diméthylsulfamoyl)-3-méthoxy-5a-[(3-méthyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4b,5,5a,6-tétrahydrocyclopropa[*d*]indolo[2,1-*a*][2]benzazépine-9-carboxamide

beclabuvir — (4b*S*,5a*R*)-12-ciclohexil-*N*-(dimetilsulfamoil)-3-metoxi-5a-[(3-metil-3,8-diazabiciclo[3.2.1]oct-8-il)carbonil]-4b,5,5a,6-tetrahidrociclopropa[*d*]indolo[2,1-*a*][2]benzazepina-9-carboxamida

$C_{36}H_{45}N_5O_5S$



begelomabum #

begelomab	immunoglobulin G2b-kappa, anti-[*Homo sapiens* DPP4(dipeptidyl-peptidase 4, dipeptidylpeptidase IV, adenosine deaminase complexing protein 2, ADCP2, TP103, T cell activation antigen CD26, CD26)], *Mus musculus* monoclonal antibody; gamma2b heavy chain (1-456) [*Mus musculus* VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -IGHG2B*02 (CH1 (121-217), hinge (218-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dimer (229-229'':232-232'':235-235'':238-238'')-tetrakisdisulfide
bégélomab	immunoglobuline G2b-kappa, anti-[*Homo sapiens* DPP4 (dipeptidyl-peptidase 4, dipeptidylpeptidase IV, protéine 2 complexant l'adénosine désaminase, ADCP2, TP103, antigène CD26 d'activation des cellules T, CD26)], *Mus musculus* anticorps monoclonal; chaîne lourde gamma2b (1-456) [*Mus musculus* VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -IGHG2B*02 (CH1 (121-217), charnière (218-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus*V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dimère (229-229'':232-232'':235-235'':238-238'')-tétrakisdisulfure
begelomab	inmunoglobulina G2b-kappa, anti-[*Homo sapiens* DPP4 (dipeptidil-peptidasa 4, dipeptidilpeptidasa IV, proteína 2 complejante de la adenosina desaminasa, ADCP2, TP103, antígeno CD26 de activación de las células T, CD26)], anticuerpo monoclonal de *Mus musculus* ; cadena pesada gamma2b (1-456) [*Mus musculus* VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -IGHG2B*02 (CH1 (121-217), bisagra (218-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dímero (229-229'':232-232'':235-235'':238-238'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGAE LVKPGASVKL SCKASGYTFR SYDINWVRQR PEQGLEWIGW  50
IFPGDGSTKY NEKFKGKATL TTDKSSSTAY MQLSRLTSED SAVYFCARWT 100
VVGPGYFDVW GAGTTVTVSS AKTTPPSVYP LAPGCGDTTG SSVTLGCLVK 150
GYFPESVTVT WNSGSLSSSV HTFPALLQSG LYTMSSSVTV PSSTWPSQTV 200
TCSVAHPASS TTVDKKLEPS GPISTINPCP PCKECHKCPA PNLEGGPSVF 250
IFPPNIKDVL MISLTPKVTC VVVDVSEDDP DVQISWFVNN VEVHTAQTQT 300
HREDYNSTIR VVSTLPIQHQ DWMSGKEFKC KVNNKDLPSP IERTISKIKG 350
LVRAPQVYIL PPPAEQLSRK DVSLTCLVVG FNPGDISVEW TSNGHTEENY 400
KDTAPVLDSD GSYFIYSKLN MKTSKWEKTD SFSCNVRHEG LKNYYLKKTI 450
SRSPGK                                                  456
```

Light chain / Chaîne légère / Cadena ligera

```
QIVLTQSPAI MSASPGEKVT ITCSASSSVS YMNWFQQKPG TSPKLWIYST  50
SNLASGVPAR FSGSGSGTSY SLTISRMEAE DAATYYCQQR SSYPNTFGGG 100
TKLEIKRADA APTVSIFPPS SEQLTSGGAS VVCFLNNFYP KDINVKWKID 150
GSERQNGVLN SWTDQDSKDS TYSMSSTLTL TKDEYERHNS YTCEATHKTS 200
TSPIVKSFNR NEC                                          213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-202	270-330	376-434
	22"-96"	147"-202"	270"-330"	376"-434"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (CH1 11-CL 126)	135-213'	135"-213'"		
Inter-H-H (h 12, h 15, h 18, h 21)	229-229"	232-232"	235-235"	238-238"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
306, 306"

benzhydrocodonum

benzhydrocodone — 4,5α-epoxy-3-methoxy-17-methyl-6,7-didehydromorphinan-6-yl benzoate

benzhydrocodone — benzoate de 4,5α-époxy-3-méthoxy-17-méthyl-6,7-didéhydromorphinan-6-yle

benzhidrocodona — benzoato de 4,5α-epoxi-17-metil-3-metoxi-6,7-dideshidromorfinan-6-ilo

$C_{25}H_{25}NO_4$



bradaniclinum

bradanicline — *N*-[(2*S*,3*R*)-2-[(pyridin-3-yl)methyl]-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide

bradanicline — *N*-[(2*S*,3*R*)-2-(pyridin-3-ylméthyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofurane-2-carboxamide

bradaniclina — *N*-[(2*S*,3*R*)-2-(piridin-3-ilmetil)-1-azabiciclo[2.2.2]oct-3-il]-1-benzofurano-2-carboxamida

$C_{22}H_{23}N_3O_2$



briciclibum

briciclib — 2-methoxy-5-({[(*E*)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl dihydrogen phosphate

briciclib — dihydrogénophosphate de 2-méthoxy-5-({[2-(2,4,6-triméthoxyphényl)éthényl]sulfonyl}méthyl)phenyl

briciclib — dihidrógenofosfato de 2-metoxi-5-({[2-(2,4,6-trimetoxifenil)etenil]sulfonil}metil)fenilo

$C_{19}H_{23}O_{10}PS$



brontictuzumabum #

brontictuzumab — immunoglobulin G2-lambda, anti-[*Homo sapiens* NOTCH1 (Notch 1, Translocation-associated notch-1, TAN-1,TAN1)], humanized monoclonal antibody;
gamma2 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1 (122-219), hinge (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)],(135-214')-disulfide with lambda light chain (1'-215') [humanized V-LAMBDA (*Homo sapiens* IGLV7-46*01 (83.20%) -IGLJ2*01) [9.3.9] (1'-109') -*Homo sapiens* IGLC7*01 (110'-215')]; dimer (223-223'':224-224'':227-227'':230-230'')-tetrakisdisulfide

brontictuzumab — immunoglobuline G2-lambda, anti-[*Homo sapiens* NOTCH1 (Notch 1, notch-1 associé aux translocations, TAN-1,TAN1)], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-447) [VH humanisé (*Homo sapiens* IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfure avec la chaîne légère lambda (1'-215') [V-LAMBDA humanisé (*Homo sapiens* IGLV7-46*01 (83.20%) -IGLJ2*01) [9.3.9] (1'-109') -*Homo sapiens* IGLC7*01 (110'-215')]; dimère (223-223'':224-224'':227-227'':230-230'')-tétrakisdisulfure

brontictuzumab	inmunoglobulina G2-lambda, anti-[NOTCH1 de *Homo sapiens* (Notch 1, notch-1 asociado a las translocaciones, TAN-1,TAN1)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-447) [VH humanizado (*Homo sapiens* IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1 (122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfuro con la cadena ligera lambda (1'-215') [V-LAMBDA humanizada (*Homo sapiens* IGLV7-46*01 (83.20%) -IGLJ2*01) [9.3.9] (1'-109') -*Homo sapiens* IGLC7*01 (110'-215')]; dímero (223-223'':224-224'':227-227'':230-230'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKI SCKVSGYTLR GYWIEWVRQA PGKGLEWIGQ  50
ILPGTGRTNY NEKFKGRVTM TADTSTDTAY MELSSLRSED TAVYYCARFD 100
GNYGYYAMDY WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVE RKCCVECPPC PAPPVAGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
QAVVTQEPSL TVSPGGTVTL TCRSSTGAVT TSNYANWFQQ KPGQAPRTLI  50
GGTNNRAPGV PARFSGSLLG GKAALTLSGA QPEDEAEYYC ALWYSNHWVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLVS DFYPGAVTVA 150
WKADGSPVKV GVETTKPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCRVTH 200
EGSTVEKTVA PAECS                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 261-321 367-425
22''-96'' 148''-204'' 261''-321'' 367''-425''
Intra-L (C23-C104) 22'-90' 137'-196'
22'''-90''' 137'''-196'''
Inter-H-L (CH1 10-CL 126) 135-214' 135''-214'''
Inter-H-H (h 4, h 5, h 8, h 11) 223-223'' 224-224'' 227-227'' 230-230''
Possible other H-L and H-H crosslinks
Inter-H-L 223-214' 223''-214'''
Inter-H-H 135-224'' 135''-224 227-227'' 230-230''
Possible other H-L and H-H crosslinks
Inter-H-L 135-214' 223''-214'''
Inter-H-H 223-135'' 224-224'' 227-227'' 230-230''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297''

butylphthalidum

butylphthalide	*rac*-3-butyl-2-benzofuran-1(3*H*)-one
butylphthalide	*rac*-3-butyl-2-benzofuran-1(3*H*)-one
butilftalida	*rac*-3-butil-2-benzofuran-1(3*H*)-ona

$C_{12}H_{14}O_2$



and enantiomer
et énantiomère
y enantiómero

cabotegravirum

cabotegravir	(3*S*,11a*R*)-*N*-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide

cabotégravir

(3*S*,11a*R*)-*N*-[(2,4-difluorophényl)méthyl]-6-hydroxy-3-méthyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide

cabotegravir

(3*S*,11a*R*)-*N*-[(2,4-difluorofenil)metil]-6-hidroxi-3-metil-5,7-dioxo-2,3,5,7,11,11a-hexahidrooxazolo[3,2-*a*]pirido[1,2-*d*]pirazina-8-carboxamida

$C_{19}H_{17}F_2N_3O_5$



capmatinibum

capmatinib

2-fluoro-*N*-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-*b*][1,2,4]triazin-2-yl}benzamide

capmatinib

2-fluoro-*N*-méthyl-4-{7-[(quinoléin-6-yl)méthyl]imidazo[1,2-*b*][1,2,4]triazin-2-yl}benzamide

capmatinib

2-fluoro-*N*-metil-4-{7-[(quinolein-6-il)metil]imidazo[1,2-*b*][1,2,4]triazin-2-il}benzamida

$C_{23}H_{17}FN_6O$



cefilavancinum

cefilavancin

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-({3-[(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,30aS_a,36*R*,38a*R*)-3-(2-amino-2-oxoethyl)-44-{[2-*O*-(3-amino-2,3,6-trideoxy-3-*C*-methyl-α-L-*lyxo*-hexopyranosyl)-β-D-glucopyranosyl]oxy}-10,19-dichloro-7,22,28,30,32-pentahydroxy-6-[(*N*-methyl-D-leucyl)amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-1*H*,22*H*-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]benzoxadiazacyclotetracosine-26-carboxamido]propoxy}imino)acetamido]-8-oxo-3-[(pyridin-1-ium-1-yl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

céfilavancine

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-({3-[(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,30aS_a,36*R*,38a*R*)-3-(2-amino-2-oxoéthyl)-44-{[2-*O*-(3-amino-2,3,6-tridéoxy-3-*C*-méthyl-α-L-*lyxo*-hexopyranosyl)-β-D-glucopyranosyl]oxy}-10,19-dichloro-7,22,28,30,32-pentahydroxy-6-[(*N*-méthyl-D-leucyl)amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tétradécahydro-1*H*,22*H*-8,11:18,21-diéthéno-23,36-(iminométhano)-13,16:31,35-diméthéno[1,6,9]oxadiazacyclohexadécino[4,5-*m*][10,2,16]benzoxadiazacyclotétracosine-26-carboxamido]propoxy}imino)acétamido]-8-oxo-3-[(pyridin-1-ium-1-yl)méthyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

cefilavancina

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-5-cloro-1,3-tiazol-4-il)-2-({3-[(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,30aS_a,36*R*,38a*R*)-3-(2-amino-2-oxoetil)-44-{[2-*O*-(3-amino-2,3,6-tridesoxi-3-*C*-metil-α-L-*lixo*-hexopiranosil)-β-D-glucopiranosil]oxi}-10,19-dicloro-7,22,28,30,32-pentahidroxi-6-[(*N*-metil-D-leucil)amino]-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahidro-1*H*,22*H*-8,11:18,21-dieteno-23,36-(iminometano)-13,16:31,35-dimeteno[1,6,9]oxadiazaciclohexadecino[4,5-*m*][10,2,16]benzoxadiazaciclotetracosina-26-carboxamido]propoxi}imino)acetamido]-8-oxo-3-[(piridin-1-io-1-il)metil]-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxilato

$C_{87}H_{95}Cl_3N_{16}O_{28}S_2$



cerdulatinibum

cerdulatinib

4-(ciclopropilamino)-2-({4-[4-(etanosulfonil)piperazin-1-il]fenil}amino)pirimidina-5-carboxamida

cerdulatinib	4-(cyclopropylamino)-2-({4-[4-(éthanesulfonyl)pipérazin-1-yl]phényl}amino)pyrimidine-5-carboxamide
cerdulatinib	4-(ciclopropilamino)-2-({4-[4-(etanosulfonil)piperazin-1-il]fenil}amino)pirimidina-5-carboxamida

$C_{20}H_{27}N_7O_3S$



cerliponasum alfa #

cerliponase alfa	immature human tripeptidyl-peptidase 1 (cell growth-inhibiting gene 1 protein, lysosomal pepstatin-insensitive protease, TPP-1, EC 3.4.14.9), 544 residues protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
cerliponase alfa	tripeptidyl-peptidase 1 humaine immature (protéine du gène 1 inhibitrice du développement cellulaire, protéase lysosomiale non-contrôlée par la pepstatine, TPP-1, EC 3.4.14.9), protéine de 544 résidus, produite par des cellules ovariennes de hamster chinois, forme glycosylée alfa
cerliponasa alfa	tripeptidil-peptidasa 1 humana inmadura (proteína del gen 1 inhibidora del desarrollo celular, proteasa lisosomial no controlada por la pepstatina, TPP-1, EC 3.4.14.9), proteína de 544 restos, producida por células ováricas de hamster chino, forma glicosilada alfa

$C_{2657}H_{4042}N_{734}O_{793}S_{11}$

Sequence / Séquence / Secuencia

```
SYSPEPDQRR TLPPGWVSLG RADPEEELSL TFALRQQNVE RLSELVQAVS 50
DPSSPQYGKY LTLENVADLV RPSPLTLHTV QKWLLAAGAQ KCHSVITQDF 100
LTCWLSIRQA ELLLPGAEFH HYVGGPTETH VVRSPHPYQL PQALAPHVDF 150
VGGLHRFPPT SSLRQRPEPQ VTGTVGLHLG VTPSVIRKRY NLTSQDVGSG 200
TSNNSQACAQ FLEQYFHDSD LAQFMRLFGG NFAHQASVAR VVGQQGRGRA 250
GIEASLDVQY LMSAGANIST WVYSSPGRHE GQEPFLQWLM LLSNESALPH 300
VHTVSYGDDE DSLSSAYIQR VNTELMKAAA RGLTLLFASG DSGAGCWSVS 350
GRHQFRPTFP ASSPYVTTVG GTSFQEPFLI TNEIVDYISG GGFSNVFPRP 400
SYQEEAVTKF LSSSPHLPPS SYFNASGRAY PDVAALSDGY WVVSNRVPIP 450
WVSGTSASTP VFGGILSLIN EHRILSGRPP LGFLNPRLYQ QHGAGLFDVT 500
RGCHESCLDE EVEGQGFCSG PGWDPVTGWG TPNFPALLKT LLNP       544
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
92-103 346-507 503-518

Glycosylation sites (N)/ Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-191 Asn-203 Asn-267 Asn-294 Asn-424

dagrocoratum

dagrocorat	(4b*S*,7*R*,8a*R*)-4b-benzyl-7-hydroxy-*N*-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide
dagrocorat	(4b*S*,7*R*,8a*R*)-4b-benzyl-7-hydroxy-*N*-(2-méthylpyridin-3-yl)-7-(trifluorométhyl)-4b,5,6,7,8,8a,9,10-octahydrophénanthrène-2-carboxamide

dagrocorat

(4b*S*,7*R*,8a*R*)-4b-bencil-7-hidroxi-*N*-(2-metilpiridin-3-il)-7-(trifluorometil)-4b,5,6,7,8,8a,9,10-octahidrofenantreno-2-carboxamida

$C_{29}H_{29}F_3N_2O_2$



dalazatidum

dalazatide

a 37-residue, synthetic peptide derivative of the *Stichodactyla* toxin:
O-phosphono-L-tyrosyl-2-[2-(2-aminoethoxy)ethoxy]acetyl[potassium channel toxin kappa-stichotoxin-Shela *Stoichactis helianthus* (Caribbean sea anemone)] peptidamide

dalazatide

peptide sythétique de 37 acides aminés dérivé de la toxine extraite de *Stichodactyla:*
O-phosphono-L-tyrosyl-2-[2-(2-aminoéthoxy)éthoxy]acétyl[toxine kappa du canal potassique-stichotoxine-Shela *Stoichactis helianthus* (anémone de mer des Antilles)] peptidamide

dalazatida

péptido sintético de 37 aminoácidos derivado de la toxina extraída de *Stichodactyla:*
O-fosfono-L-tirosil-2-[2-(2-aminoetoxi)etoxi]acetil[toxina kappa del canal de potasio-stichotoxina-Shela *Stoichactis helianthus* (anémona del Mar de las Antillas)] peptidamida

$C_{184}H_{296}N_{57}O_{55}PS_7$

Sequence / Séquence / Secuencia
YXRSCIDTIP KSRCTAFQCK HSMKYRLSFC RKTCGTC 37

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
5-37 14-30 19-34

Modified residues / Résidus modifiés / Restos modificados
X (2) 2-[2-(2-aminoethoxy)ethoxy]acetic acid



dapaconazolum

dapaconazole

1-[*rac*-2-(2,4-dichlorophenyl)-2-{[4-(trifluoromethyl)phenyl]methoxy}ethyl]-1*H*-imidazole

dapaconazole

1-[*rac*-2-(2,4-dichlorophényl)-2-{[4-(trifluorométhyl)phényl]méthoxy}éthyl]-1*H*-imidazole

dapaconazol

1-[*rac*-2-(2,4-diclorofenil)-2-{[4-(trifluorometil)fenil]metoxi}etil]-1*H*-imidazol

$C_{19}H_{15}Cl_2F_3N_2O$



and enantiomer
et énantiomère
y enantiómero

defactinibum

defactinib — *N*-methyl-4-({4-({[3-(*N*-methylmethanesulfonamido)pyrazin-2-yl]methyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide

défactinib — *N*-méthyl-4-({4-({[3-(*N*-méthylméthanesulfonamido)pyrazin-2-yl]méthyl}amino)-5-(trifluorométhyl)pyrimidin-2-yl}amino)benzamide

defactinib — *N*-metil-4-({4-({[3-(*N*-metilmetanesulfonamido)pirazin-2-il]metil}amino)-5-(trifluorometil)pirimidin-2-il}amino)benzamida

$C_{20}H_{21}F_3N_8O_3S$



denintuzumabum mafodotinum #

denintuzumab mafodotin — immunoglobulin G1-kappa auristatin F conjugate, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], humanized monoclonal antibody; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens* IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01) [10.7.12] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin F (MMAF), via a noncleavable maleimidocaproyl (mc) linker

For the *mafodotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

dénintuzumab mafodotine

immunoglobuline G1-kappa conjuguée à l'auristatine F, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens* IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01) [10.7.12] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine F (MMAF), via un linker maléimidocaproyl (mc) non clivable

Pour la partie *mafodotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

denintuzumab mafodotina

inmunoglobulina G1-kappa conjugada con la auristatina F, anti-[CD19 de *Homo sapiens* (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01) [10.7.12] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en 4 restos cisteinil por término medio, con monometilauristatina F (MMAF), mediante un conector maleimidocaproil (mc) no escindible

La fracción *mafodotina*, pueden encontrarla en el documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS TSGMGVGWIR QHPGKGLEWI  50
GHIWWDDDKR YNPALKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARM 100
ELWSYYFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCSASSSVS YMHWYQQKPG QAPRLLIYDT  50
SKLASGIPAR FSGSGSGTDF TLTISSLEPE DVAVYYCFQG SVYPFTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	147-203	264-324	370-428
	22"-97"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23'"-87'"	133'"-193'"		
Inter-H-L (h 5-CL 126) *	223-213'	223"-213'"		
Inter-H-H (h 11, h 14) *	229-229"	232-232"		

*Two inter-chain disulfide bridges are not present on average, the antibody being conjugated to an average of 4 drug linkers, each bound to a cysteinyl via a thioether bond
*Deux des ponts disulfure inter-chaines ne sont pas présents en moyenne, l'anticorps étant conjugué à une moyenne de 4 linker-principe actif, chacun via une liaison thioéther.
* Faltan dos puentes disulfuro intercatenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 4 conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"

dianhydrogalactitolum
dianhydrogalactitol — *meso*-(1*R*,2*S*)-1-[(2*R*)-oxiran-2-yl]-2-[(2*S*)-oxiran-2-yl]ethane-1,2-diol

dianhydrogalactitol — *méso*-(1*R*,2*S*)-1-[(2*R*)-oxiran-2-yl]-2-[(2*S*)-oxiran-2-yl]éthane-1,2-diol

dianhidrogalactitol — *meso*-(1*R*,2*S*)-1-[(2*R*)-oxiran-2-il]-2-[(2*S*)-oxiran-2-il]etano-1,2-diol

$C_6H_{10}O_4$



diclofenaci etalhyaluronas
diclofenac etalhyaluronate — hyaluronic acid partly amidified with 2-(2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetyloxy)ethanamine

étalhyaluronate de diclofénac — acide hyaluronique partiellement amidifié par la 2-(2-{2-[(2,6-dichlorophényl)amino]phényl}acétyloxy)éthanamine

etalhialuronato de diclofenaco — ácido hialurónico parcialmente amidificado por 2-(2-{2-[(2,6-diclorofenil)amino]fenil}acetiloxi)etanamina

$[(C_{30}H_{35}Cl_2N_3O_{12})_a(C_{14}H_{21}NO_{11})_b]_nH_2O$



diridavumabum #
diridavumab — immunoglobulin G1-lambda2, anti-[influenza A virus hemagglutinin HA2 subunit (H1, H2, H5, H6, H8 and H9 subtypes)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14](1-121) -IGHG1*03 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS K2>del (450)(122-450)],(224-216')-disulfide with lambda2 light chain(1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimer (230-230'':233-233'')-bisdisulfide

diridavumab

immunoglobuline G1-lambda2, anti-[sous-unité HA2 de l'hémagglutinine du virus de la grippe A (sous-types H1, H2, H5, H6, H8 et H9)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14](1-121) -IGHG1*03 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS K2>del (450)(122-450)],(224-216')-disulfure avec la chaîne légère lambda2 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimère (230-230'':233-233'')-bisdisulfure

diridavumab

inmunoglobulina G1-lambda2, anti-[subunidad HA2 de la hemaglutinina del virus de la gripe A (sub-tipos H1, H2, H5, H6, H8 y H9)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14] (1-121) -IGHG1*03 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS K2>del (450) (122-450)], (224-216')-disulfuro con la cadena ligera lambda2 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero (230-230'':233-233'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
```
EVQLVESGAE VKKPGSSVKV SCKASGGPFR SYAISWVRQA PGQGPEWMGG  50
IIPIFGTTKY APKFQGRVTI TADDFAGTVY MELSSLRSED TAMYYCAKHM 100
GYQVRETMDV WGKGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera
```
QSVLTQPPSV SAAPGQKVTI SCSGSSSNIG NDYVSWYQQL PGTAPKLLIY  50
DNNKRPSGIP DRFSGSKSGT SATLGITGLQ TGDEANYYCA TWDRRPTAYV 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 22'-89' 139'-198'
22'"-89"' 139'"-198'"
Inter-H-L (h 5-CL 126) 224-216' 224"-216'"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"

Other post-translational modifications
Autres modifications post-traductionnelles
Otras modificaciones post-traduccionales
Lacking H chain C-terminal lysine (CHS K2>del)

eflapegrastimum #
eflapegrastim

human granulocyte colony-stimulating factor and human IgG4 Fc dimer linked together with polyethylene glycol derivative, produced in *Escherichia coli*: $N^{\alpha.1}$,$N^{1.9'}$-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyethylene)] des-(1-L-alanine,37-39)-[18-L-serine(C>S),69-L-serine(P>S)]human granulocyte colony-stimulating factor (G-CSF, pluripoietin) (1-174)-peptide and des-(1-8)-human immunoglobulin G4 Fc fragment (IGHG4*01 H-CH2-CH3) (9'-229')-peptide dimer (11'-11'')-disulfide

éflapégrastim

le facteur de stimulation de colonies de granulocytes humain et le dimère du fragment Fc de l'IgG4 humaine, produits par *Escherichia coli*, reliés par un radical substituant dérivé du polyéthylèneglycol: $N^{\alpha.1}$,$N^{1.9'}$-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyethylene)] dès-(1-L-alanine,37-39)-[18-L-sérine(C>S), 69-L-sérine(P>S)]facteur de stimulation de colonies de granulocytes humain (G-CSF, pluripoiétine) (1-174)-peptide et (11'-11'')-disulfure du dimère de dès-(1-8)-fragment Fc de l'immunoglobuline G4 humaine (IGHG4*01 H-CH2-CH3) (9'-229')-peptide

eflapegrastim

producto de la unión, mediante un radical derivado del polietilenglicol, del factor estimulante de colonias de granulocitos humano y el dímero del fragmento Fc de la IgG4 humana, producidos por *Escherichia coli*. $N^{\alpha.1}$,$N^{1.9'}$-[ω-(oxipropano-1,3-diil)-α-(propano-1,3-diil)poli(oxietileno)] des-(1-L-alanina,37-39)-[18-L-serina(C>S),69-L-serina(P>S)]]factor estimulante de colonias de granulocitos humano (G-CSF, pluripoyetina) (1-174)-péptido y (11'-11'')-disulfuro del dímero de des-(1-8)-fragmento Fc de la inmunoglobulina G4 humana (IGHG4*01 H-CH2-CH3) (9'-229')-péptido

Human G-CSF derivative sequence / Séquence dérivée du G-CSF humain / Secuencia derivada de G-CSF humano

```
TPLGPASSLP QSFLLKSLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
GHSLGIPWAP LSSCSSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
VLVASHLQSF LEVSYRVLRH LAQP                          174
```

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4

```
        PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50'
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100'
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150'
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200'
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK                     229'
```

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4

```
        PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50''
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100''
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150''
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200''
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK                     229''
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
11'-11'' 36-42 43'-103' 43''-103'' 64-74 149'-207' 149''-207''

Modified residues / Résidus modifiés / Restos modificados



efmoroctocogum alfa #
efmoroctocog alfa

recombinant DNA derived (1-742)-(1637-2332)-human blood coagulation factor VIII fusion protein with immunoglobulin G1 Fc domain fragment, produced in HEK293H cells, glycoform alfa:
des-(743-1636)-human blood coagulation factor VIII (antihemophilic factor, procoagulant component) fusion protein with human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (1444-6':1447-9')-bisdisulfide with human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide

efmoroctocog alfa

(1-742)-(1637-2332)-facteur VIII de coagulation humain protéine de fusion avec le fragment Fc de l'immunoglobuline G1, produite dans les cellules HEK293H à partir d'ADN recombinant, forme glycosylée alfa: dès-(743-1636)-facteur VIII de coagulation humain (facteur antihémophilique, composé procoagulant) protéine de fusion avec le fragment Fc de l'immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (1444-6':1447-9')-bisdisulfure avec le fragment Fc de l'immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide

efmoroctocog alfa

(1-742)-(1637-2332)-factor VIII de coagulación humano proteína de fusión con el fragmento Fc de la inmunoglobulina G1, producida en las células HEK293H a partir de ADN recombinante, forma glicosilada alfa: des-(743-1636)-factor VIII de coagulación humano (factor antihemofílico, componente procoagulante) proteína de fusión con el fragmento Fc de la inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido (1444-6':1447-9')-bisdisulfuro con el fragmento Fc de la inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido

Fusion protein / Protéine de fusion / Proteína de fusión

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNPPVLK 750
RHQREITRTT LQSDQEEIDY DDTISVEMKK EDFDIYDEDE NQSPRSFQKK 800
TRHYFIAAVE RLWDYGMSSS PHVLRNRAQS GSVPQFKKVV FQEFTDGSFT 850
QPLYRGELNE HLGLLGPYIR AEVEDNIMVT FRNQASRPYS FYSSLISYEE 900
DQRQGAEPRK NFVKPNETKT YFWKVQHHMA PTKDEFDCKA WAYFSDVDLE 950
KDVHSGLIGP LLVCHTNTLN PAHGRQVTVQ EFALFFTIFD ETKSWYFTEN 1000
MERNCRAPCN IQMEDPTFKE NYRFHAINGY IMDTLPGLVM AQDQRIRWYL 1050
LSMGSNENIH SIHFSGHVFT VRKKEEYKMA LYNLYPGVFE TVEMLPSKAG 1100
IWRVECLIGE HLHAGMSTLF LVYSNKCQTP LGMASGHIRD FQITASGQYG 1150
QWAPKLARLH YSGSINAWST KEPFSWIKVD LLAPMIIHGI KTQGARQKFS 1200
SLYISQFIIM YSLDGKKWQT YRGNSTGTLM VFFGNVDSSG IKHNIFNPPI 1250
IARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMESKA ISDAQITASS 1300
YFTNMFATWS PSKARLHLQG RSNAWRPQVN NPKEWLQVDF QKTMKVTGVT 1350
TQGVKSLLTS MYVKEFLISS SQDGHQWTLF FQNGKVKVFQ GNQDSFTPVV 1400
NSLDPPLLTR YLRIHPQSWV HQIALRMEVL GCEAQDLYDK THTCPPCPAP 1450
ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV 1500
EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI 1550
EKTISKAKGQ PREPQVYTLP PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE 1600
SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL 1650
HNHYTQKSLS LSPG                                        1664
```

Immunoglobulin Fc fragment / fragment Fc d'immunoglobuline / fragmento Fc de inmunoglobulina

```
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 50'
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 100'
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK 150'
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 200'
NVFSCSVMHE ALHNHYTQKS LSLSPG                           226'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

6'-1444 9'-1447 41'-101' 147'-205' 153-179 248-329 528-554
630-711 938-964 1005-1009 1127-1275 1280-1432 1479-1539 1585-1643

Modified residues / Résidus modifiés / Restos modificados

Y
346, 718, 719, 723, 770, 786
O-sulfoTyr



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-77' Asn-239 Asn-916 Asn-1224 Asn-1515

efpeglenatidum #

efpeglenatide

exenatide derivative and human IgG4 Fc dimer linked together with polyethylene glycol derivative: $N^{6.27}$,$N^{1.9'}$-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyethylene)] [1-(imidazol-4-ylacetic acid)]exendin-4 *Heloderma suspectum* (Gila monster), human immunoglobulin G4 Fc fragment-(9'-229')-peptide dimer (11'-11")-disulfide

efpèglénatide

dérivé de l'exénatide et du dimère de l'IgG4 Fc liés par un pont dérivé du polyéthylèneglycol : $N^{6.27}$,$N^{1.9'}$-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyéthylène)] [1-acide (imidazol-4-yl)acétique]exendine-4 *Heloderma suspectum* (monstre de Gila), fragment Fc de l'immunoglobuline G4 humaine-(9'-229')-peptide (11'-11")-disulfure du dimère

efpeglenatida

derivado de la exenatida y del dímero de la IgG4 Fc unidos por un puente derivado del polietilenglicol : $N^{6.27}$,$N^{1.9'}$-[ω-(oxipropano-1,3-diil)-α-(propano-1,3-diil)poli(oxitileno)] [1-ácido (imidazol-4-il)acético]exendina-4 *Heloderma suspectum* (monstruo de Gila), fragmento Fc de la inmunoglobulina G4 humana-(9'-229')-péptido (11'-11")-disulfuro del dímero

Modified exendin-4 / Exendine-4 modifiée / Exendina-4 modificada

```
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS              39
```

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero del Fc de hIGHG4

```
        PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50'
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100'
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150'
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200'
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK   229'
```

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero del Fc de hIGHG4

```
        PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50''
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100''
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150''
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200''
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK   229''
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

11'-11" 43'-103' 43"-103" 149'-207' 149"-207"

Modified residues / Résidus modifiés / Restos modificados



emactuzumabum #

emactuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimer (225-225":228-228")-bisdisulfide

émactuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens*IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)],(219-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (225-225":228-228")-bisdisulfure

emactuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CSF1R (receptor del factor 1 estimulante de colonias, CSF-1R, CSF-1-R, receptor del factor 1 estimulante de colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYDISWVRQA PGQGLEWMGV  50
IWTDGGTNYA QKLQGRVTMT TDTSTSTAYM ELRSLRSDDT AVYYCARDQR 100
LYFDVWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASEDVN TYVSWYQQKP GKAPKLLIYA  50
ASNRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SFSYPTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	143-199	260-320	366-424
	22"-95"	143"-199"	260"-320"	366"-424"
Intra-L (C23-C104)	23'-88'	133'-193'		
	23"'-88"'	133"'-193"'		
Inter-H-L (h 5-CL 126)	219-213'	219"-213"'		
Inter-H-H (h 11, h 14)	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"

emibetuzumabum #

emibetuzumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor receptor, HGFR, scatter factor receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-Met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody;
gamma4 heavy chain (1-441) [humanized VH (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-115)), IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)],(129-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.40%) -IGKJ4*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (221-221":224-224")-bisdisulfide

émibétuzumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-441) [VH humanisé (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-115)), IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)], (129-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (84.40%) -IGKJ4*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (221-221":224-224")-bisdisulfure

emibetuzumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* MET (proto-oncogén met, receptor del factor de crecimiento de hepatocitos, HGFR, receptor del factor de dispersión, receptor del HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de células renales 2, RCCP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-441) [VH humanizada (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-115)) , IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)], (129-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (84.40%) -IGKJ4*01) [7.3.9] (1'-108')-*Homo sapiens* IGKC*01 (109'-215')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYYMHWVRQA PGQGLEWMGR  50
VNPNRRGTTY NQKFEGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARAN 100
WLDYWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV 200
DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL G          441
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCSVSSSVS SIYLHWYQQK PGKAPKLLIY  50
STSNLASGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ VYSGYPLTFG 100
GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	142-198	256-316	362-420
	22"-96"	142"-198"	256"-316"	362"-420"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (CH1 10-CL 126)	129-215'	129"-215'"		
Inter-H-H (h 8, h 11)	221-221"	224-224"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
292, 292"

Other post-translational modifications
Autres modifications post-traductionnelles
Otras modificaciones post-traduccionales
Lacking H chain C-terminal lysine (CHS K2>del)

enadenotucirevum #

enadenotucirev	chimeric oncolytic adenovirus Ad3/Ad11p containing two deletions in the viral genome in the E3 region (2444 bp) and in the E4 region (24 bp) and 197 non-homologous nucleotides in the E2B region
énadénotucirev	adénovirus chimérique oncolytique Ad3/Ad11p contenant deux suppressions dans le génome viral, dans la région E3 (2444 pb) et dans la région E4 (24 pb) et 197 nucléotides non-homologues dans la région E2B
enadenotucirev	adenovirus quimérico oncolítico Ad3/Ad11p que contiene dos delecciones en el genoma viral, en la región E3 (2444 pb) y en la región E4 (24 pb) y 197 nucléotidos no-homólogos en la región E2B

enceniclinum

encenicline	*N*-[(3*R*)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
encénicline	*N*-[(3*R*)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophène-2-carboxamide
enceniclina	*N*-[(3*R*)-1-azabiciclo[2.2.2]octan-3-il]-7-cloro-1-benzotiofeno-2-carboxamida

$C_{16}H_{17}ClN_2OS$



esuberaprostum

esuberaprost	(+)-4-{(1*R*,2*R*,3a*S*,8b*S*)-2-hydroxy-1-[(1*E*,3*S*,4*S*)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl}butanoic acid
ésubéraprost	(+)-acide4-{(1*R*,2*R*,3a*S*,8b*S*)-2-hydroxy-1-[(1*E*,3*S*,4*S*)-3-hydroxy-4-méthyloct-1-én-6-yn-1-yl]-2,3,3a,8b-tétrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl}butanoïque
esuberaprost	(+)-ácido 4-{(1*R*,2*R*,3a*S*,8b*S*)-2-hidroxi-1-[(1*E*,3*S*,4*S*)-3-hidroxi-4-metiloct-1-en-6-in-1-il]-2,3,3a,8b-tetrahidro-1*H*-ciclopenta[*b*][1]benzofuran-5-il}butanoico

$C_{24}H_{30}O_5$



evofosfamidum

evofosfamide — (1-methyl-2-nitro-1*H*-imidazol-5-yl)methyl *N*,*N*'-bis(2-bromoethyl)phosphorodiamidate

évofosfamide — *N*,*N*'-bis(2-bromoéthyl)phosphorodiamidate de (1-méthyl-2-nitro-1*H*-imidazol-5-yl)méthyle

evofosfamida — *N*,*N*'-bis(2-bromoetil)fosforodiamidato de (1-metil-2-nitro-1*H*-imidazol-5-il)metilo

$C_9H_{16}Br_2N_5O_4P$



ferricum maltolum

ferric maltol — tris(2-methyl-4-oxo-κ*O*-4*H*-pyran-3-olato-κ*O*)iron(III)

maltol ferrique — tris(2-méthyl-4-oxo-κ*O*-4*H*-pyran-3-olato-κ*O*)fer(III)

maltol férrico — tris(2-metil-4-oxo-κ*O*-4*H*-piran-3-olato-κ*O*)hierro(III)

$C_{18}H_{15}FeO_9$



filociclovirum

filociclovir — 2-amino-9-{(*Z*)-[2,2-bis(hydroxymethyl)cyclopropylidene]methyl}-1,9-dihydro-6*H*-purin-6-one

filociclovir	2-amino-9-{(*Z*)-[2,2-bis(hydroxyméthyl)cyclopropylidène]méthyl}-1,9-dihydro-6*H*-purin-6-one
filociclovir	2-amino-9-{(*Z*)-[2,2-bis(hidroximetil)ciclopropilideno]metil}-1,9-dihidro-6*H*-purin-6-ona

$C_{11}H_{13}N_5O_3$



firivumabum #

firivumab	immunoglobulin G1-kappa, anti-[influenza A virus hemagglutinin HA], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*03 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G (437) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (232-232":235-235")-bisdisulfide
firivumab	immunoglobuline G1-kappa, anti-[hémagglutinine HA du virus de la grippe A], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*03 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G (437) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-232":235-235")-bisdisulfure
firivumab	inmunoglobulina G1-kappa, anti-[hemaglutinina HA del virus de la gripe A], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-453) [*Homo sapiens* VH (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*03 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G (437) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKMPGSSVKV SCKTSGVFFS SHAISWVRQA PGQGLEWMGG  50
ISPMFGTTHY AQKFQGRVTI TADQSTTTAY MELTSLTSED TAVYYCARDG 100
AGSYYPLNWF DPWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEGLHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASENIW NNLAWYQQKP GQAPRLLISG  50
ASTGATGVPS RFRGSGSRTE FTLTISSLQS EDFAIYFCQQ YNSWPRTFGP 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	150-206	267-327	373-431
	22"-96"	150"-206"	267"-327"	373"-431"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	226-214'	226"-214'"		
Inter-H-H (h 11, h 14)	232-232"	235-235"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 303"

fosdagrocoratum

fosdagrocorat — (2*R*,4a*S*,10a*R*)-4a-benzyl-7-[(2-methylpyridin-3-yl)carbamoyl]-2-(trifluoromethyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-2-yl dihydrogen phosphate

fosdagrocorat — dihydrogénophosphate de (2*R*,4a*S*,10a*R*)-4a-benzyl-7-[(2-méthylpyridin-3-yl)carbamoyl]-2-(trifluorométhyl)-1,2,3,4,4a,9,10,10a-octahydrophénanthrén-2-yle

fosdagrocorat — dihidrógenofosfato de (2*R*,4a*S*,10a*R*)-4a-bencil-7-[(2-metilpiridin-3-il)carbamoil]-2-(trifluorometil)-1,2,3,4,4a,9,10,10a-octahidrofenantren-2-ilo

$C_{29}H_{30}F_3N_2O_5P$



funapidum

funapide — (3'*S*)-1'-{[5-(trifluoromethyl)furan-2-yl]methyl}-2*H*,6*H*-spiro[furo[2,3-*f*][1,3]benzodioxole-7,3'-indol]-2'(1'*H*)-one

funapide — (3'*S*)-1'-{[5-(trifluorométhyl)furan-2-yl]méthyl}-2*H*,6*H*-spiro[furo[2,3-*f*][1,3]benzodioxole-7,3'-indol]-2'(1'*H*)-one

funapida — (3'*S*)-1'-{[5-(trifluorometil)furan-2-il]metil}-2*H*,6*H*-espiro[furo[2,3-*f*][1,3]benzodioxol-7,3'-indol]-2'(1'*H*)-ona

$C_{22}H_{14}F_3NO_5$



furaprevirum

furaprevir — cyclopentyl {(2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-14a-[(1-methylcyclopropane-1-sulfonamido)carbonyl]-2-[(2-{4-[(propan-2-yl)oxy]phenyl}benzofuro[3,2-*d*]pyrimidin-4-yl)oxy]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl}carbamate

furaprévir — {(2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-14a-[(1-méthylcyclopropane-1-sulfonamido)carbonyl]-2-[(2-{4-[(propan-2-yl)oxy]phényl}benzofuro[3,2-*d*]pyrimidin-4-yl)oxy]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadécahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécin-6-yl}carbamate de cyclopentyle

furaprevir — {(2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-14a-[(1-metilciclopropano-1-sulfonamido)carbonil]-2-[(2-{4-[(propan-2-il)oxi]fenil}benzofuro[3,2-*d*]pirimidin-4-il)oxi]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecin-6-il}carbamato de ciclopentilo

$C_{47}H_{56}N_6O_{10}S$



gedatolisibum

gedatolisib — *N*-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-*N*'-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}urea

gédatolisib — *N*-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-*N*'-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phényl}urée

gedatolisib

N-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-*N*'-{4-[4,6-di(morfolin-4-il)-1,3,5-triazin-2-il]fenil}urea

$C_{32}H_{41}N_9O_4$



glasdegibum

glasdegib

N-[(2*R*,4*R*)-2-(1*H*-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-*N*'-(4-cyanophenyl)urea

glasdégib

N-[(2*R*,4*R*)-2-(1*H*-benzimidazol-2-yl)-1-méthylpipéridin-4-yl]-*N*'-(4-cyanophényl)urée

glasdegib

N-[(2*R*,4*R*)-2-(1*H*-benzoimidazol-2-il)-1-metilpiperidin-4-il]-*N*'-(4-cianofenil)urea

$C_{21}H_{22}N_6O$



idasanutlinum

idasanutlin

4-[(2*R*,3*S*,4*R*,5*S*)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxamido]-3-methoxybenzoic acid

idasanutline

acide 4-[(2*R*,3*S*,4*R*,5*S*)-3-(3-chloro-2-fluorophényl)-4-(4-chloro-2-fluorophényl)-4-cyano-5-(2,2-diméthylpropyl)pyrrolidine-2-carboxamido]-3-méthoxybenzoïque

idasanutlina

ácido 4-[(2*R*,3*S*,4*R*,5*S*)-3-(3-cloro-2-fluorofenil)-4-(4-cloro-2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)pirrolidina-2-carboxamido]-3-metoxibenzoico

$C_{31}H_{29}Cl_2F_2N_3O_4$



imalumabum #

imalumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* MIF (macrophage migration inhibitory factor, glycosylation-inhibiting factor, GLIF, GIF)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -IGHG1*03 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide

imalumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* MIF (facteur inhibiteur de la migration des macrophages, facteur inhibant la glycosylation, GLIF, GIF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -IGHG1*03 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure

imalumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* MIF (facteur inhibidor de la migración de macrófagos, factor inhibidor de la glicosilación, GLIF, GIF)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -IGHG1*03 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfuro con la cadena kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS  50
IGSSGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAGSQ 100
WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV  50
ASHSQSGVPS RFRGSGSETD FTLTISGLQP EDSATYYCQQ SFWTPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 221-214' 221"-214'"
Inter-H-H (h 11, h 14) 227-227'" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"

indoximodum

indoximod — 1-methyl-D-tryptophan

indoximod — 1-méthyl-D-tryptophane

indoximod — 1-metil-D-triptófano

$C_{12}H_{14}N_2O_2$



lemborexantum

lemborexant — (1*R*,2*S*)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-*N*-(5-fluoropyridin-2-yl)cyclopropanecarboxamide

lemborexant — (1*R*,2*S*)-2-{[(2,4-diméthylpyrimidin-5-yl)oxy]méthyl}-2-(3-fluorophényl)-*N*-(5-fluoropyridin-2-yl)cyclopropanecarboxamide

lemborexant — (1*R*,2*S*)-2-{[(2,4-dimetilpirimidin-5-il)oxi]metil}-2-(3-fluorofenil)-*N*-(5-fluoropiridin-2-il)ciclopropanocarboxamida

$C_{22}H_{20}F_2N_4O_2$



lenzilumabum #

lenzilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide

lenzilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure

lenzilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CSF2 (factor 2 estimulante de colonias (granulocitos-macrófagos), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYSFT NYYIHWVRQA PGQRLEWMGW  50
INAGNGNTKY SQKFQGRVTI TRDTSASTAY MELSSLRSED TAVYYCVRRQ 100
RFPYYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSVSPGERAT LSCRASQSVG TNVAWYQQKP GQAPRVLIYS  50
TSSRATGITD RFSGSGSGTD FTLTISRLEP EDFAVYYCQQ FNKSPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	222-214'	222"-214'"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"

Ionoctocogum alfa #

Ionoctocog alfa

recombinant DNA derived B domain deleted single-chain human blood coagulation factor VIII, produced in Chinese hamster ovary (CHO) D944 cells, glycoform alfa: des-(765-1652)-human blood coagulation factor VIII (antihemophilic factor, procoagulant component)

Ionoctocog alfa

facteur VIII de coagulation humain dont le domaine B a été supprimé, chaîne unique, produit par les cellules ovariennes de hamsters chinois (CHO) D944 à partir d'ADN recombinant, forme glycosylée alfa; dès-(765-1652)-facteur VIII de coagulation humain (facteur antihémophilique, composé procoagulant)

Ionoctocog alfa

factor VIII de coagulación humano al que se ha suprimido el dominio B, monocatenario, producido por células ováricas de hamster chino (CHO) D944 a partir de ADN recombinante, forma glicosilada alfa; des-(765-1652)-factor VIII de coagulación humano (factor antihemofílico, componente procoagulante)

Sequence / Séquence / Secuencia

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750
TRQKQFNATT IPENTTLQSD QEEIDYDDTI SVEMKKEDFD IYDEDENQSP 800
RSFQKKTRHY FIAAVERLWD YGMSSSPHVL RNRAQSGSVP QFKKVVFQEF 850
TDGSFTQPLY RGELNEHLGL LGPYIRAEVE DNIMVTFRNQ ASRPYSFYSS 900
LISYEEDQRQ GAEPRKNFVK PNETKTYFWK VQHHMAPTKD EFDCKAWAYF 950
SDVDLEKDVH SGLIGPLLVC HTNTLNPAHG RQVTVQEFAL FFTIFDETKS 1000
WYFTENMERN CRAPCNIQME DPTFKENYRF HAINGYIMDT LPGLVMAQDQ 1050
RIRWYLLSMG SNENIHSIHF SGHVFTVRKK EEYKMALYNL YPGVFETVEM 1100
LPSKAGIWRV ECLIGEHLHA GMSTLFLVYS NKCQTPLGMA SGHIRDFQIT 1150
ASGQYGQWAP KLARLHYSGS INAWSTKEPF SWIKVDLLAP MIIHGIKTQG 1200
ARQKFSSLYI SQFIIMYSLD GKKWQTYRGN STGTLMVFFG NVDSSGIKHN 1250
IFNPPIIARY IRLHPTHYSI RSTLRMELMG CDLNSCSMPL GMESKAISDA 1300
QITASSYFTN MFATWSPSKA RLHLQGRSNA WRPQVNNPKE WLQVDFQKTM 1350
KVTGVTTQGV KSLLTSMYVK EFLISSSQDG HQWTLFFQNG KVKVFQGNQD 1400
SFTPVVNSLD PPLLTRYLRI HPQSWVHQIA LRMEVLGCEA QDLY       1444
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 944-970 1011-1015 1133-1281 1286-1438

Modified residues / Résidus modifiés / Restos modificados

Y
346-718-719-723-776-792
O-sulfoTyr



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-757 Asn-764 Asn-922 Asn-1230
Glycosylation site (O) / Site de glycosylation (O) / Posición de glicosilación (O)
Ser-743

Iulizumabum pegolum #

Iulizumab pegol

immunoglobulin V-kappa pegylated, anti-[*Homo sapiens* CD28 (TP44, T cell specific surface glycoprotein CD28)], humanized monoclonal antibody;
V-kappa domain (1-107) [humanized V-KAPPA (*Homo sapiens* IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01 G119>S (99)) [6.3.9] (1-107)] -arginyl (108); conjugated via a linker of the maleimide group (thioether bond with cysteinyl 86 (70)) to two linear chains of methoxy polyethylene glycol 20 (mPEG20)

lulizumab pégol	immunoglobuline V-kappa pégylé, anti-[*Homo sapiens* CD28 (TP44, glycoprotéine de surface CD28 spécifique des cellules T)], anticorps monoclonal humanisé; domaine V-kappa (1-107) [V-KAPPA humanisé (*Homo sapiens* IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01 G119>S (99)) [6.3.9] (1-107)] -arginyl (108); conjugué via un linker du groupe maléimide (liaison thioéther avec cystéinyl 86 (70)) à deux chaînes linéaires de méthoxy polyéthylène glycol 20 (mPEG20)
lulizumab pegol	inmunoglobulina V-kappa pegilada, anti-[*Homo sapiens* CD28 (TP44, glicoproteína de superficie CD28 específico de células T)], anticuerpo monoclonal humanizado; dominio V-kappa (1-107) [V-KAPPA humanizado (*Homo sapiens* IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01 G119>S (99)) [6.3.9] (1-107)] -arginil (108); conjugado mediante conector del grupo maleimida (unión tioéter con cisteinil 86 (70)) con dos cadenas lineales de metoxi polietilen glicol 20 (mPEG20)

```
DIQMTQSPSS LSASVGDRVT ITCRASRPIW PFLEWYQQKP GKAPKLLIYF  50
TSRLRHGVPS RFSGSGSGTC FTLTISSLQP EDFATYYCLQ NVANPATFSQ 100
GTKVEIKR                                               108
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-L (C23-C104) 23-88

Pegylation site / Site de pegylation / Posición de pegilación
D86>C:
70

lumretuzumabum #

lumretuzumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], humanized monoclonal antibody; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01(CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)],(223-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dimer (229-229":232-232")-bisdisulfide
lumrétuzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01(CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)],(223-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dimère (229-229":232-232")-bisdisulfure

lumretuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFR SSYISWVRQA PGQGLEWMGW  50
IYAGTGSPSY NQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARHR 100
DYYSNSLTYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSQSVL NSGNQKNYLT WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQSDYSY 100
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                  220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-94'	140'-200'		
	23'"-94'"	140'"-200'"		
Inter-H-L (h 5-CL 126)	223-220'	223"-220'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Enriched in bisected non-fucosylated oligosaccharides
Enrichi en oligosaccharides non-fucosylés bissectés
Enriquecido con oligosacáridos bisecados no fucosilados

Other post-translational modifications
Autres modifications post-traductionnelles
Otras modificaciones post-traduccionales
Lacking H chain C-terminal lysine (CHS K2>del)

merotocinum
merotocin

N-(4-sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-*N*-[(4-fluorophenyl)methyl]glycyl-L-leucylglycinamide cyclic (1-5)-thioether

mérotocine

(1-5)-thioéthercyclique du *N*-(4-sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cystéinyl-*N*-[(4-fluorophényl)méthyl]glycyl-L-leucylglycinamide

merotocina

(1-5)-tioetercíclico del *N*-(4-sulfanilbutanoil)-L-tirosil-L-isoleucil-L-glutaminil-L-asparaginil-L-cisteinil-*N*-[(4-fluorofenil)metil]glicil-L-leucilglicinamida

$C_{48}H_{68}FN_{11}O_{12}S$



mibenratidum

mibenratide

an 18 amino acid cyclic peptide largely homologous to amino acids 202-220 of the β_1-adrenergic receptor second extracellular loop (AR-ECII) that binds to anti-β1-AR pathological autoantibodies:
cyclo(L-alanyl-L-arginyl-L-arginyl-L-cysteinyl-L-tyrosyl-L-asparaginyl-L-α-aspartyl-L-prolyl-L-lysyl-L-cysteinyl-L-seryl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-alanyl-L-α-aspartyl-L-α-glutamyl), cyclic (4-10)-disulfide

mibenratide

peptide cyclique de 18 acides aminés largement homologue aux acides aminés 202-220 de la seconde boucle extracellulaire de l'adrénorécepteur β_1 (AR-ECII) qui se lie aux autoanticorps anti-β1-AR pathologiques:
(4-10)-disulfure cyclique du cyclo(L-alanyl-L-arginyl-L-arginyl-L-cystéinyl-L-tyrosyl-L-asparaginyl-L-α-aspartyl-L-prolyl-L-lysyl-L-cystéinyl-L-séryl-L-α-aspartyl-L-phénylalanyl-L-valyl-L-glutaminyl-L-alanyl-L-α-aspartyl-L-α-glutamyl)

mibenratida

péptido cíclico de 18 aminoácidos altamente homólogo a los aminoácidos 202-220 del segundo bucle extracelular del adrenoreceptor β_1 (AR-ECII) que se une a los autoanticuerpos anti-β1-AR patológicos:
(4-10)-disulfuro cíclico del ciclo (L-alanil-L-arginil-L-arginil-L-cisteinil-L-tirosil-L-asparaginil-L-α-aspartil-L-prolil-L-lisil-L-cisteinil-L-seril-L-α-aspartil-L-fenilalanil-L-valil-L-glutaminil-L-alanil-L-α-aspartil-L-α-glutamil)

$C_{87}H_{129}N_{27}O_{30}S_2$



modimelanotidum

modimelanotide

acetylhexa-L-lysyl[human melanotropin alpha (alpha-MSH)]

modimélanotide

acétylhexa-L-lysyl[mélanotropine alpha humaine (alpha-MSH)]

modimelanotida

acetilhexa-L-lisil[melanotropina alfa humana (alfa-MSH)]

$C_{113}H_{181}N_{33}O_{25}S$



mongersenum

mongersen

all-P-ambo-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxycytidine

mongersen

tout-P-ambo-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxycytidine

mongersén

todo-P-ambo-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioctidlil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxicitidina

$C_{200}H_{261}N_{69}O_{107}P_{20}S_{20}$

(3'-5')d(*P*-thio)(G-T-m^{5}C-G-C-C-C-C-T-T-C-T-C-C-C-m^{5}C-G-C-A-G-C)



napabucasinum

napabucasin

2-acetylnaphtho[2,3-*b*]furan-4,9-dione

napabucasine

2-acétylnaphtho[2,3-*b*]furan-4,9-dione

napabucasina

2-acetilnafto[2,3-*b*]furan-4,9-diona

$C_{14}H_8O_4$



odalasvirum

odalasvir — dimethyl *N*,*N*′-(1,4(1,4)-dibenzenacyclohexaphane-1^2,4^2-diylbis{1*H*-benzimidazole-5,2-diyl[(2*S*,3a*S*,7a*S*)-octahydro-1*H*-indole-2,1-diyl][(2*S*)-3-methyl-1-oxobutan-1,2-diyl]})biscarbamate

odalasvir — *N*,*N*′-(1,4(1,4)-dibenzénacyclohexaphane-1^2,4^2-diylbis{1*H*-benzimidazole-5,2-diyl[(2*S*,3a*S*,7a*S*)-octahydro-1*H*-indole-2,1-diyl][(2*S*)-3-méthyl-1-oxobutan-1,2-diyl]})biscarbamate de diméthyle

odalasvir — *N*,*N*′-(1,4(1,4)-dibencenaciclohexafano-1^2,4^2-diilbis{1*H*-benzoimidazol-5,2-diil[(2*S*,3a*S*,7a*S*)-octahidro-1*H*-indol-2,1-diil][(2*S*)-3-metil-1-oxobutan-1,2-diil]})biscarbamato de dimetilo

$C_{60}\ H_{72}\ N_8\ O_6$



olipudasum alfa #

olipudase alfa — recombinant DNA derived des-(1-13)-human sphingomyelin phosphodiesterase (acid sphingomyelinase, EC-3.1.4.12), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

olipudase alfa — dès-(1-13)-sphingomyéline phosphodiesterase humaine (sphingomyélinase acide, EC-3.1.4.12), produite par des cellules ovariennes de hamster chinois à partir d'ADN recombinant, forme glycosylée alfa

olipudasa alfa — des-(1-13)-esfingomielina fosfodiesterasa humana (esfingomielinasa ácida, EC-3.1.4.12), producida en células ováricas de hamster chino a partir de ADN recombinante, forma glicosilada alfa

Sequence / Séquence / Secuencia

```
                HPLSPQG HPARLHRIVP RLRDVFGWGN LTCPICKGLF 50
TAINLGLKKE PNVARVGSVA IKLCNLLKIA PPAVCQSIVH LFEDDMVEVW 100
RRSVLSPSEA CGLLLGSTCG HWDIFSSWNI SLPTVPKPPP KPPSPPAPGA 150
PVSRILFLTD LHWDHDYLEG TDPDCADPLC CRRGSGLPPA SRPGAGYWGE 200
YSKCDLPLRT LESLLSGLGP AGPFDMVYWT GDIPAHDVWH QTRQDQLRAL 250
TTVTALVRKF LGPVPVYPAV GNHESTPVNS FPPPFIEGNH SSRWLYEAMA 300
KAWEPWLPAE ALRTLRIGGF YALSPYPGLR LISLNMNFCS RENFWLLINS 350
TDPAGQLQWL VGELQAAEDR GDKVHIIGHI PPGHCLKSWS WNYYRIVARY 400
ENTLAAQFFG HTHVDEFEVF YDEETLSRPL AVAFLAPSAT TYIGLNPGYR 450
VYQIDGNYSG SSHVVLDHET YILNLTQANI PGAIPHWQLL YRARETYGLP 500
NTLPTAWHNL VYRMRGDMQL FQTFWFLYHK GHPPSEPCGT PCRLATLCAQ 550
LSARADSPAL CRHLMPDGSL PEAQSLWPRP LFC                   583
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
43-119 46-111 74-85 175-180 181-204 339-385 538-542 548-561

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-40 Asn-129 Asn-289 Asn-349 Asn-457 Asn-474

omipalisibum
omipalisib — 2,4-difluoro-*N*-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzenesulfonamide

omipalisib — 2,4-difluoro-*N*-{2-méthoxy-5-[4-(pyridazin-4-yl)quinoléin-6-yl]pyridin-3-yl}benzènesulfonamide

omipalisib — 2,4-difluoro-*N*-{2-metoxi-5-[4-(piridazin-4-il)quinolein-6-il]piridin-3-il}bencenosulfonamida

$C_{25}H_{17}F_2N_5O_3S$



orilotimodum
orilotimod — D-γ-glutamyl-D-tryptophan

orilotimod — D-γ-glutamyl-D-tryptophane

orilotimod — D-γ-glutamil-D-triptófano

$C_{16}H_{19}N_3O_5$



paritaprevirum
paritaprevir — (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-*N*-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecine-14a(5*H*)-carboxamide

paritaprévir

(2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-*N*-(cyclopropylsulfonyl)-6-(5-méthylpyrazin-2-carboxamido)-5,16-dioxo-2-(phénanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tétradécahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécine-14a(5*H*)-carboxamide

paritaprevir

(2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-*N*-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahidrociclopropa[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecina-14a(5*H*)-carboxamida

$C_{40}H_{43}N_7O_7S$



pasotuxizumabum #

pasotuxizumab

immunoglobulin scFv-scFv, anti-[*Homo sapiens* FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], humanized and chimeric monoclonal antibody bispecific single chain;
scFv anti-FOLH1 (1-243) [humanized VH (*Homo sapiens* IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14](1-121)-15-mer tris(tetraglycyl-seryl) linker (122-136) -humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G (236)) [6.3.9](137-243)] -6-mer seryl-tetraglycyl-seryl linker (244-249) -scFv anti-CD3E (250-498) [*Mus musculus* VH (*Mus musculus* IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer tris(tetraglycyl-seryl) linker (375-389) -humanized V-LAMBDA (*Homo sapiens* IGLV7-43*01(85.10%)-IGLJ3*02 [9.3.9] (390-498)] -hexahistidine (499-504)

pasotuxizumab

immunoglobuline scFv-scFv, anti-[*Homo sapiens* FOLH1 (folate hydrolase, antigène membranaire spécifique de la prostate, PSMA)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticorps monoclonal humanisé et chimérique bispécifique à chaîne unique;
scFv anti-FOLH1(1-243) [VH humanisé (*Homo sapiens* IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14](1-121)-15-mer tris(tétraglycyl-séryl) linker (122-136) - V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G (236)) [6.3.9](137-243)] -6-mer séryl-tétraglycyl-séryl linker (244-249) -scFv anti-CD3E (250-498) [*Mus musculus* VH (*Mus musculus* IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer tris(tétraglycyl-séryl) linker (375-389) – V-LAMBDA humanisé (*Homo sapiens* IGLV7-43*01(85.00%)-IGLJ3*02 [9.3.9] (390-498)] -hexahistidine (499-504)

pasotuxizumab

inmunoglobulina scFv-scFv, anti-[*Homo sapiens* FOLH1 (folato hidrolasa, antígeno de membrana específico de la próstata, PSMA)]/anti-[*Homo sapiens* CD3E (CD3 épsilon)], anticuerpo monoclonal humanizado y quimérico biespecífico monocatenario;
IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14] (1-121) -15-mer tris(tetraglicil-seril) conector (122-136) - V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G (236)) [6.3.9] (137-243)] -6-mer seril-tetraglicil-seril conector (244-249) -scFv anti-CD3E (250-498) [*Mus musculus* VH (*Mus musculus* IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer tris(tetraglicil-seril) conector 375-389) -V-LAMBDA humanizado (*Homo sapiens* IGLV7-43*01(85.00%)-IGLJ3*02 [9.3.9] (390-498)] -hexahistidina (499-504)

```
QVQLVESGGG LVKPGESLRL SCAASGFTFS DYYMYWVRQA PGKGLEWVAI  50
ISDGGYYTYY SDIIKGRFTI SRDNAKNSLY LQMNSLKAED TAVYYCARGF 100
PLLRHGAMDY WGQGTLVTVS SGGGGSGGGG SGGGGSDIQM TQSPSSLSAS 150
VGDRVTITCK ASQNVDTNVA WYQQKPGQAP KSLIYSASYR YSDVPSRFSG 200
SASGTDFTLT ISSVQSEDFA TYYCQQYDSY PYTFGGGTKL EIKSGGGGSE 250
VQLVESGGGL VQPGGSLKLS CAASGFTFNK YAMNWVRQAP GKGLEWVARI 300
RSKYNNYATY YADSVKDRFT ISRDDSKNTA YLQMNNLKTE DTAVYYCVRH 350
GNFGNSYISY WAYWGQGTLV TVSSGGGGSG GGGSGGGGSQ TVVTQEPSLT 400
VSPGGTVTLT CGSSTGAVTS GNYPNWVQQK PGQAPRGLIG GTKFLAPGTP 450
ARFSGSLLGG KAALTLSGVQ PEDEAEYYCV LWYSNRWVFG GGTKLTVLHH 500
HHHH                                                    504
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain C23 C104 22-96 159-224 271-347 411-479

patidegibum

patidegib

N-[(2*S*,3*R*,3'*R*,3a*S*,4'a*R*,6*S*,6'a*R*,6'b*S*,7a*R*,12'a*S*,12'b*S*)-3,6,11',12'b-tetramethyl-2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-icosahydro-1'*H*,3*H*-spiro[furo[3,2-*b*]pyridine-2,9'-naphtho[2,1-*a*]azulen]-3'-yl]methanesulfonamide

patidégib

N-[(2*S*,3*R*,3'*R*,3a*S*,4'a*R*,6*S*,6'a*R*,6'b*S*,7a*R*,12'a*S*,12'b*S*)-3,6,11',12'b-tétraméthyl-2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-icosahydro-1'*H*,3*H*-spiro[furo[3,2-*b*]pyridine-2,9'-naphto[2,1-*a*]azulen]-3'-yl]méthanesulfonamide

patidegib

N-[(2*S*,3*R*,3'*R*,3a*S*,4'a*R*,6*S*,6'a*R*,6'b*S*,7a*R*,12'a*S*,12'b*S*)-3,6,11',12'b-tetrametil-2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-icosahidro-1'*H*,3*H*-espiro[furo[3,2-*b*]piridina-2,9'-nafto[2,1-*a*]azulen]-3'-il]metanosulfonamida

$C_{29}H_{48}N_2O_3S$



peficitinibum

peficitinib — 4-{[(1*R*,2*s*,3*S*,5*s*,7*s*)-5-hydroxyadamantan-2-yl]amino}-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxamide

péficitinib — 4-{[(1*R*,2*s*,3*S*,5*s*,7*s*)-5-hydroxyadamantan-2-yl]amino}-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxamide

peficitinib — 4-{[(1*R*,2*s*,3*S*,5*s*,7*s*)-5-hidroxiadamantan-2-il]amino}-1*H*-pirrolo[2,3-*b*]piridina-5-carboxamida

$C_{18}H_{22}N_4O_2$



pegargiminasum #

pegargiminase — [111-glutamic acid,209-serine]arginine deiminase (ADI, arginine dihydrolase, AD) from *Mycoplasma hominis*, an average of five amino groups are amidified with 4-[ω-methoxypoly(oxyethylene)]-4-oxobutanoyl, produced in *Escherichia coli*

pégargiminase — [111-acide glutamique,209-sérine]arginine désiminase (ADI, arginine dihydrolase, AD) de *Mycoplasma hominis,* produite par *Escherichia coli,* et dont cinq groupes amino, en moyenne, sont amidifiés par le 4-[ω-méthoxypoly(oxyéthylène)]-4-oxobutanoyle

pegargiminasa — [111-ácido glutámico,209-seria]arginina desiminasa (ADI, arginina dihidrolasa, AD) de *Mycoplasma hominis,* producida en *Escherichia coli,* en la cual 5 grupos amino por término medio, están amidificado por 4-[ω-metoxipoli(oxietileno)]-4-oxobutanoilo

$C_{2091}H_{3276}N_{540}O_{607}S_{15}$ $((C_5H_6O_3(C_2H_4O)_n)_a$

Sequence / Séquence / Secuencia

```
SVFDSKFNGI HVYSEIGELE TVLVHEPGRE IDYITPARLD ELLFSAILES 50
HDARKEHQSF VKIMKDRGIN VVELTDLVAE TYDLASKAAK EEFIETFLEE 100
TVPVLTEANK EAVRAFLLSK PTHEMVEFMM SGITKYELGV ESENELIVDP 150
MPNLYFTRDP FASVGNGVTI HFMRYIVRRR ETLFARFVFR NHPKLVKTPW 200
YYDPAMKMSI EGGDVFIYNN ETLVVGVSER TDLDTITLLA KNIKANKEVE 250
FKRIVAINVP KWTNLMHLDT WLTMLDKNKF LYSPIANDVF KFWDYDLVNG 300
GAEPQPQLNG LPLDKLLASI INKEPVLIPI GGAGATEMEI ARETNFDGTN 350
YLAIKPGLVI GYDRNEKTNA ALKAAGITVL PFHGNQLSLG MGNARCMSMP 400
LSRKDVKW                                              408
```

Potential modified residues* / Résidus modifiables* / Restos potencialemente modificados*



* an average of 5 (*a*) out of 28 are pegylated / 5 (*a*) sur les 28 sont en moyenne pégylés / 5 *(a)* cada 28 por término medio están pegilados

pegcrisantaspasum #

pegcrisantaspase

recombinant L-asparaginase derived from *Erwinia chrysanthemi* pegylated with 5 kDa methoxy polyethylene glycol (m-PEG-NHS), produced in *Escherichia coli*: L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) *Erwinia chrysanthemi* tetramer α_4, an average of 10 (*a*) out of 18 amino groups of each monomer are amidified with 5-{[α-methylpoly(oxyethylene)]amino}-5-oxopentanoyl

pegcrisantaspase

L-asparaginase recombinante dérivée d'*Erwinia chrysanthemi* pégylée par du méthoxy polyéthylène glycol (m-PEG-NHS) de 5kDa, produite par *Escherichia coli*: tétramère α_4 de la L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) d'*Erwinia chrysanthemi* dont 10 (*a*) groupes amino, en moyenne, sur les 18 de chaque monomère sont amidifiés par le radical substituant 5-{[α-méthylpoly(oxyéthylène)]amino}-5-oxopentanoyle

pegcrisantaspasa

L-asparaginasa recombinante derivada de *Erwinia chrysanthemi* pegilada por metoxi polietilenglicol (m-PEG-NHS) de 5kDa, producida en *Escherichia coli*: tetrámero α_4 de la L-asparaginasa (EC 3.5.1.1, L-asparagina amidohidrolasa) d'*Erwinia chrysanthemi* de la cual 10 (*a*) grupos amino, por término medio, de los 18 de cada monómero están amidificados por 5-{[α-metilpoli(oxietileno)]amino}-5-oxopentanoilo

$C_{1546}H_{2510}N_{432}O_{476}S_9(C_6H_9NO_2[C_2H_4O]_n)_a$ (monomer)

Monomer sequence / Séquence du monomère/ Secuencia del monómero

```
ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK AGALGVDTLI NAVPEVKKLA 50
NVKGEQFSNM ASENMTGDVV LKLSQRVNEL LARDDVDGVV ITHGTDTVEE 100
SAYFLHLTVK SDKPVVFVAA MRPATAISAD GPMNLLEAVR VAGDKQSRGR 150
GVMVVLNDRI GSARYITKTN ASTLDTFKAN EEGYLGVIIG NRIYYQNRID 200
KLHTTRSVFD VRGLTSLPKV DILYGYQDDP EYLYDAAIQH GVKGIVYAGM 250
GAGSVSVRGI AGMRKAMEKG VVVIRSTRTG NGIVPPDEEL PGLVSDSLNP 300
AHARILLMLA LTRTSDPKVI QEYFHTY                         327
```

Potential modified residues / Résidus modifiés potentiels / Restos potencialmente modificados



pegvaliasum #

pegvaliase

pegylated, recombinant DNA derived *Anabaena variabilis* phenylalanine ammonia lyase mutein (S 503, S 565), produced in *Escherichia coli*: [503,565-diserine (C>S)]phenylalanine ammonia-lyase (EC 4.3.1.24) *Anabaena variabilis* in which an average of 5 lysyl residues are N^6-{6-[ω-methoxypoly(oxyethylene)]hexanoyl} substituted

pegvaliase

mutéine (S 503, S 565) de phénylalanine ammoniac-lyase de *Anabaena variabilis*, pégylée, produite par *Escherichia coli* à partir d'ADN recombinant: [503,565-disérine (C>S)]phénylalanine ammoniac-lyase (EC 4.3.1.24) de *Anabaena variabilis* dont une moyenne de 5 résidus lysyl sont N^6-{6-[ω-méthoxypoly(oxyéthylène)]hexanoyl} substitués

pegvaliasa

muteína (S 503, S 565) de la fenilalanina amoniaco-liasa de *Anabaena variabilis*, pegilada, producida en *Escherichia coli* a partir de ADN recombinante: [503,565-diserine (C>S)]fenilalanina amoniaco-liase (EC 4.3.1.24) de *Anabaena variabilis* de cuyos restos lisil 5, por término medio, están N^6-{6-[ω-metoxipoli(oxietileno)]hexanoil} substituidos

$C_{2726}H_{4321}N_{763}O_{828}S_{20}\,(C_7H_{12}O_2[C_2H_4O]_n)_a$

Sequence / Séquence / Secuencia

```
MKTLSQAQSK TSSQQFSFTG NSSANVIIGN QKLTINDVAR VARNGTLVSL 50
TNNTDILQGI QASCDYINNA VESGEPIYGV TSGFGGMANV AISREQASEL 100
QTNLVWFLKT GAGNKLPLAD VRAAMLLRAN SHMRGASGIR LELIKRMEIF 150
LNAGVTPYVY EFGSIGASGD LVPLSYITGS LIGLDPSFKV DFNGKEMDAP 200
TALRQLNLSP LTLLPKEGLA MMNGTSVMTG IAANCVYDTQ ILTAIAMGVH 250
ALDIQALNGT NQSFHPFIHN SKPHPGQLWA ADQMISLLAN SQLVRDELDG 300
KHDYRDHELI QDRYSLRCLP QYLGPIVDGI SQIAKQIEIE INSVTDNPLI 350
DVDNQASYHG GNFLGQYVGM GMDHLRYYIG LLAKHLDVQI ALLASPEFSN 400
GLPPSLLGNR ERKVNMGLKG LQICGNSIMP LLTFYGNSIA DRFPTHAEQF 450
NQNINSQGYT SATLARRSVD IFQNYVAIAL MFGVQAVDLR TYKKTGHYDA 500
RASLSPATER LYSAVRHVVG QKPTSDRPYI WNDNEQGLDE HIARISADIA 550
AGGVIVQAVQ DILPSLH                                    567
```

Modified residues / Résidus modifiés / Restos modificados

ASG
167-168-169
Dianhydroderivative



K
10, 32, 115, 145, 195, 301, 335, 413, 493, 494, 522
Partly pegylated Lysyl
Lysyl partiellement pégylé
Lisil parcialmente pegilado



polmacoxibum

polmacoxib

4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl]-benzenesulfonamide

polmacoxib

4-[3-(3-fluorophényl)-5,5-diméthyl-4-oxo-4,5-dihydrofuran-2-yl]-benzènesulfonamide

polmacoxib

4-[3-(3-fluorofenil)-5,5-dimetil-4-oxo-4,5-dihidrofuran-2-il]-bencenosulfonamida

$C_{18}H_{16}FNO_4S$



presatovirum

presatovir

N-(2-{[(2*S*)-2-{5-[(3*S*)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-*a*]pyrimidin-2-yl}piperidin-1-yl]carbonyl}-4-chlorophenyl)methanesulfonamide

présatovir

N-(2-{[(2*S*)-2-{5-[(3*S*)-3-aminopyrrolidin-1-yl]-6-méthylpyrazolo[1,5-*a*]pyrimidin-2-yl}pipéridin-1-yl]carbonyl}-4-chlorophényl)méthanesulfonamide

presatovir

N-(2-{[(2*S*)-2-{5-[(3*S*)-3-aminopirrolidin-1-il]-6-metilpirazolo[1,5-*a*]pirimidin-2-il}piperidin-1-il]carbonil}-4-clorofenil)metanosulfonamida

$C_{24}H_{30}ClN_7O_3S$



rabacfosadinum

rabacfosadine

diethyl *N*,*N*'-[({2-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]ethoxy}methyl)phosphinylidene]bis-L-alaninate

rabacfosadine

N,*N*'-[({2-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]éthoxy}méthyl)phosphinylidène]bis-L-alaninate de diéthyle

rabacfosadina

N,*N*'-[({2-[2-amino-6-(ciclopropilamino)-9*H*-purin-9-il]etoxi}metil)fosfinilideno]bis-L-alaninato de dietilo

$C_{21}H_{35}N_8O_6P$



rapastinelum

rapastinel

L-threonyl-L-prolyl-L-prolyl-L-threoninamide

rapastinel

L-thréonyl-L-prolyl-L-prolyl-L-thréoninamide

rapastinel

L-treonil-L-prolil-L-prolil-L-treoninamida

$C_{18}H_{31}N_5O_6$



relenopridum

relenopride — 4-amino-*N*-[(1-{(3*S*)-3-[(carbamoyl)oxy]-3-(4-fluorophenyl)propyl}-piperidin-4-yl)methyl]-5-chloro-2-methoxybenzamide

rélénopride — 4-amino-*N*-[(1-{(3*S*)-3-[(carbamoyl)oxy]-3-(4-fluorophényl)propyl}-pipéridin-4-yl)méthyl]-5-chloro-2-méthoxybenzamide

relenoprida — 4-amino-*N*-[(1-{(3*S*)-3-[(carbamoil)oxi]-3-(4-fluorofenil)propil}-piperidin-4-il)metil]-5-cloro-2-metoxibenzamida

$C_{24}H_{30}ClFN_4O_4$



reveglucosidasum alfa #

reveglucosidase alfa — des-(2-7)-human insulin-like growth factor II fusion protein with glycyl-L-alanyl-L-prolyl-human lysosomal alpha-glucosidase (acid maltase, aglucosidase alfa) produced in Chinese hamster ovary (CHO) cells, glycoform alfa

révéglucosidase alfa — dès-(2-7)-facteur II de croissance humain semblable à l'insuline, protéine de fusion avec la glycyl-L-alanyl-L-prolyl-alpha-glucosidase lysosomiale humaine (maltase acide, aglucosidase alfa), forme gylcosylée alfa produite par des cellules ovariennes de hamster chinois (CHO)

reveglucosidasa alfa — des-(2-7)-factor II de crecimiento humano semejante a la insulina, proteína de fusión con la glicil-L-alanil-L-prolil-alfa-glucosidasa lisosómica humana (maltasa ácida, aglucosidasa alfa), forma glicosilada alfa, producida por células ováricas de hamster chino (CHO)

$C_{4735}H_{7189}N_{1261}O_{1371}S_{38}$

Sequence / Séquence / Secuencia

```
ALCGGELVDT LQFVCGDRGF YFSRPASRVS RRSRGIVEEC CFRSCDLALL 50
ETYCATPAKS EGAPAHPGRP RAVPTQCDVP PNSRFDCAPD KAITQEQCEA 100
RGCCYIPAKQ GLQGAQMGQP WCFFPPSYPS YKLENLSSSE MGYTATLTRT 150
TPTFFPKDIL TLRLDVMMET ENRLHFTIKD PANRRYEVPL ETPHVHSRAP 200
SPLYSVEFSE EPFGVIVHRQ LDGRVLLNTT VAPLFFADQF LQLSTSLPSQ 250
YITGLAEHLS PLMLSTSWTR ITLWNRDLAP TPGANLYGSH PFYLALEDGG 300
SAHGVFLLNS NAMDVVLQPS PALSWRSTGG ILDVYIFLGP EPKSVVQQYL 350
DVVGYPFMPP YWGLGFHLCR WGYSSTAITR QVVENMTRAH FPLDVQWNDL 400
DYMDSRRDFT FNKDGFRDFP AMVQELHQGG RRYMMIVDPA ISSSGPAGSY 450
RPYDEGLRRG VFITNETGQP LIGKVWPGST AFPDFTNPTA LAWWEDMVAE 500
FHDQVPFDGM WIDMNEPSNF IRGSEDGCPN NELENPPYVP GVVGGTLQAA 550
TICASSHQFL STHYNLHNLY GLTEAIASHR ALVKARGTRP FVISRSTFAG 600
HGRYAGHWTG DVWSSWEQLA SSVPEILQFN LLGVPLVGAD VCGFLGNTSE 650
ELCVRWTQLG AFYPFMRNHN SLLSLPQEPY SFSEPAQQAM RKALTLRYAL 700
LPHLYTLFHQ AHVAGETVAR PLFLEFPKDS STWTVDHQLL WGEALLITPV 750
LQAGKAEVTG YFPLGTWYDL QTVPIEALGS LPPPPAAPRE PAIHSEGQWV 800
TLPAPLDTIN VHLRAGYIIP LQGPGLTTTE SRQQPMALAV ALTKGGEARG 850
ELFWDDGESL EVLERGAYTQ VIFLARNNTI VNELVRVTSE GAGLQLQKVT 900
VLGVATAPQQ VLSNGVPVSN FTYSPDTKVL DICVSLLMGE QFLVSWC    947
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
3-41 15-54 40-45 77-103 87-104 98-122 528-553 642-653 933-947

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-135 Asn-228 Asn-465 Asn-487 Asn-647 Asn-877 Asn-920

revusiranum

revusiran

[(2*S*,4*R*)-1-{30-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-diazahexadecyl]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen 2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroadenylate duplex with 2'-*O*-methyl-*P*-thiocytidylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyluridine

révusiran

duplex de l'hydrogéno-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroadénylate de [(2*S*,4*R*)-1-{30-(2-acétamido-2-déoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-acétamido-2-déoxy-β-D-galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-diazahexadécyl]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]méthyle,avec le 2'-*O*-méthyl-*P*-thiocytidylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthyluridine

revusirán

dúplex del hidrógeno-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilato de [(2*S*,4*R*)-1-{30-(2-acetamido-2-desoxi-β-D-galactopiranosil)-14,14-bis[16-(2-acetamido-2-desoxi-β-D-galactopiranosil)-5,11-dioxo-2,16-dioxa-6,10-diazahexadecil]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoil}-4-hidroxipirolidin-2-il]metilo, con el 2'-*O*-metil-*P*-tiocitidilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metiluridina

$C_{517}H_{676}F_{22}N_{171}O_{314}P_{43}S_2$

[(3'-5') U-G-G-A-U-U-C-A-U-G-U-A-A-C-C-A-A-G-A-R1]
. . . . . .
[(5'-3') Cs-Us-A-C-C-C-U-A-A-A-G-U-A-C-A-U-U-G-G-U-U-C-U]

Legend
X = 2'-deoxy-2'-fluoro
X = 2'-*O*-methyl
- = -PO_2H-
s- = -POSH-



ribociclibum

ribociclib

7-cyclopentyl-*N*,*N*-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxamide

ribociclib

7-cyclopentyl-*N*,*N*-diméthyl-2-{[5-(pipérazin-1-yl)pyridin-2-yl]amino}-7*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxamide

ribociclib

7-ciclopentil-*N*,*N*-dimetil-2-{[5-(piperazin-1-il)piridin-2-il]amino}-7*H*-pirrolo[2,3-*d*]pirimidina-6-carboxamida

$C_{23}H_{30}N_8O$



rimiducidum

rimiducid — 1,1'-{ethane-1,2-diylbis[azanediyl(2-oxoethan-2,1-diyl)oxy-3,1-phenylene]bis[(1*R*)-3-(3,4-dimethoxyphenyl)propyl] bis{(2*S*)-1-[(2*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl]-piperidine-2-carboxylate}

rimiducid — bis{(2*S*)-1-[(2*S*)-2-(3,4,5-triméthoxyphényl)butanoyl]pipéridine-2-carboxylate} de 1,1'-{éthane-1,2-diylbis[azanediyl(2-oxoéthan-2,1-diyl)oxy-3,1-phénylène]bis[(1*R*)-3-(3,4-diméthoxyphényl)propyl]

rimiducid — bis{(2*S*)-1-[(2*S*)-2-(3,4,5-trimetoxifenil)butanoil]piperidina-2-carboxilato} de 1,1'-{etano-1,2-diilbis[azanodiil(2-oxoetan-2,1-diil)oxi-3,1-fenileno]bis[(1*R*)-3-(3,4-dimetoxifenil)propil]

$C_{78}H_{98}N_4O_{20}$



rociletinibum

rociletinib — *N*-[3-({2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl}amino)phenyl]prop-2-enamide

rocilétinib — *N*-[3-({2-[4-(4-acétylpipérazin-1-yl)-2-méthoxyanilino]-5-(trifluorométhyl)pyrimidin-4-yl}amino)phényl]prop-2-énamide

rociletinib

N-[3-({2-[4-(4-acetilpiperazin-1-il)-2-metoxianilino]-5-(trifluorometil)pirimidin-4-il}amino)fenil]prop-2-enamida

$C_{27}H_{28}F_3N_7O_3$



rurioctocogum alfa pegolum #

rurioctocog alfa pegol

pegylated recombinant DNA derived human blood coagulation factor VIII, produced in Chinese hamster ovary (CHO cells), glycoform alfa:
human blood coagulation factor VIII (antihemophilic factor, procoagulant component)-(1-1648)-peptide associated to (1649-2332)-peptide, glycoform alfa produced in CHO cells, some of its lysine residues are N^6 substituted with 4-[1,3-bis({[α-methylpoly(oxyethylene)]carbamoyl}oxy)propan-2-yloxy]butanoyl radicals

rurioctocog alfa pégol

facteur VIII de coagulation humain, produit par des cellules ovariennes de hamster chinois à partir d'ADN recombinant, pégylé, forme glycosylée alfa;
association des peptides (1-1648)- et (1649-2332)- du facteur VIII de coagulation humain (facteur antihémophilique, composé procoagulant) produite par des cellules ovariennes de hamster chinois sous forme glycosylée alfa dont quelques résidus lysine sont N^6 substitués par le radical 4-[1,3-bis({[α-méthylpoly(oxyéthylène)]carbamoyl}oxy)propan-2-yloxy]butanoyle

rurioctocog alfa pegol

factor VIII de coagulación humano, producido por células ováricas de hamster chino a partir de ADN recombinante, pegilado, forma glicosilada alfa;
asociación de péptidos (1-1648)- y (1649-2332)- del factor VIII de coagulación humano (factor antihémofílico, componente procoagulante) producido por células ováricas de hamster chino en forma glicosilada alfa algunos de cuyos restos lisina están N^6 substituidos por radicales 4-[1,3-bis({[α-metilpoli(oxietileno)]carbamoil}oxi)propan-2-iloxi]butanoilo

Heavy chain / Chaîne lourde / Cadena pesada

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750
TRQKQFNATT IPENDIEKTD PWFAHRTPMP KIQNVSSSDL LMLLRQSPTP 800
HGLSLSDLQE AKYETFSDDP SPGAIDSNNS LSEMTHFRPQ LHHSGDMVFT 850
PESGLQLRLN EKLGTTAATE LKKLDFKVSS TSNNLISTIP SDNLAAGTDN 900
TSSLGPPSMP VHYDSQLDTT LFGKKSSPLT ESGGPLSLSE ENNDSKLLES 950
GLMNSQESSW GKNVSSTESG RLFKGKRAHG PALLTKDNAL FKVSISLLKT 1000
NKTSNNSATN RKTHIDGPSL LIENSPSVWQ NILESDTEFK KVTPLIHDRM 1050
LMDKNATALR LNHMSNKTTS SKNMEMVQQK KEGPIPPDAQ NPDMSFFKML 1100
FLPESARWIQ RTHGKNSLNS GQGPSPKQLV SLGPEKSVEG QNFLSEKNKV 1150
VVGKGEFTKD VGLKEMVFPS SRNLFLTNLD NLHENNTHNQ EKKIQEEIEK 1200
KETLIQENVV LPQIHTVTGT KNFMKNLFLL STRQNVEGSY DGAYAPVLQD 1250
FRSLNDSTNR TKKHTAHFSK KGEEENLEGL GNQTKQIVEK YACTTRISPN 1300
TSQQNFVTQR SKRALKQFRL PLEETELEKR IIVDDTSTQW SKNMKHLTPS 1350
TLTQIDYNEK EKGAITQSPL SDCLTRSHSI PQANRSPLPI AKVSSFPSIR 1400
PIYLTRVLFQ DNSSHLPAAS YRKKDSGVQE SSHFLQGAKK NNLSLAILTL 1450
EMTGDQREVG SLGTSATNSV TYKKVENTVL PKPDLPKTSG KVELLPKVHI 1500
YQKDLFPTET SNGSPGHLDL VEGSLLQGTE GAIKWNEANR PGKVPFLRVA 1550
TESSAKTPSK LLDPLAWDNH YGTQIPKEEW KSQEKSPEKT AFKKKDTILS 1600
LNACESNHAI AAINEGQNKP EIEVTWAKQG RTERLCSQNP PVLKRHQR   1648
```

Light chain / Chaîne légère / Cadena ligera

```
                                                      EI 1650
TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700
AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750
ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000
LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050
ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100
FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300
LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY                   2332
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Modified residues / Résidus modifiés / Restos modificados



* potential pegylated residues / résidus pouvant être pégylés / restos potencialmente pegilados

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-582 Asn-757 Asn-784 Asn-828 Asn-900 Asn-943
Asn-963 Asn-1001 Asn-1005 Asn-1055 Asn-1066 Asn-1185 Asn-1255
Asn-1259 Asn-1282 Asn-1300 Asn-1412 Asn-1442 Asn-1810 Asn-2118

sarolanerum

sarolaner	1-{5'-[(5*S*)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl]-3'-*H*-spiro[azetidine-3,1'-[2]benzofuran]-1-yl}-2-(methanesulfonyl)ethanone
sarolaner	1-{5'-[(5*S*)-5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl]-3'-*H*-spiro[azétidine-3,1'-[2]benzofuran]-1-yl}-2-(méthanesulfonyl)éthanone

sarolaner

1-{5'-[(5*S*)-5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-4,5-dihidroisoxazol-3-il]-3'-*H*-espiro[azetidina-3,1'-[2]benzofuran]-1-il}-2-(metilsulfonil)etanona

$C_{23}H_{18}Cl_2F_4N_2O_5S$



savolitinibum

savolitinib

1-[(1*S*)-1-(imidazo[1,2-*a*]pyridin-6-yl)ethyl]-6-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-1,2,3-triazolo[4,5-*b*]pyrazine

savolitinib

1-[(1*S*)-1-(imidazo[1,2-*a*]pyridin-6-yl)éthyl]-6-(1-méthyl-1*H*-pyrazol-4-yl)-1*H*-1,2,3-triazolo[4,5-*b*]pyrazine

savolitinib

1-[(1*S*)-1-(imidazo[1,2-*a*]piridin-6-il)etil]-6-(1-metil-1*H*-pirazol-4-il)-1*H*-1,2,3-triazolo[4,5-*b*]pirazina

$C_{17}H_{15}N_9$



sembragilinum

sembragiline

N-[(3*S*)-1-{4-[(3-fluorophenyl)methoxy]phenyl}-5-oxopyrrolidin-3-yl]acetamide

sembragiline

N-[(3*S*)-1-{4-[(3-fluorophényl)méthoxy]phényl}-5-oxopyrrolidin-3-yl]acétamide

sembragilina

N-[(3*S*)-1-{4-[(3-fluorofenil)metoxi]fenil}-5-oxopirrolidin-3-il]acetamida

$C_{19}H_{19}FN_2O_3$



tenofovirum alafenamidum

tenofovir alafenamide

propan-2-yl *N*-[(*S*)-({[(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy}methyl)phenoxyphosphinoyl]-L-alaninate

ténofovir alafénamide

N-[(*S*)-({[(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy}méthyl)phénoxyphosphinoyl]-L-alaninate de propan-2-yle

tenofovir alafenamida

N-[(*S*)-({[(2*R*)-1-(6-amino-9*H*-purin-9-il)propan-2-il]oxi}metil)fenoxifosfinoil]-L-alaninato de propan-2-ilo

$C_{21}H_{29}N_6O_5P$



tepotinibum

tepotinib

3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin-3-yl}benzonitrile

tépotinib

3-{1-[(3-{5-[(1-méthylpipéridin-4-yl)méthoxy]pyrimidin-2-yl}phényl)méthyl]-6-oxo-1,6-dihydropyridazin-3-yl}benzonitrile

tepotinib

3-{1-[(3-{5-[(1-metilpiperidin-4-il)metoxi]pirimidin-2-il}fenil)metil]-6-oxo-1,6-dihidropiridazin-3-il}benzonitrilo

$C_{29}H_{28}N_6O_2$



tradipitantum

tradipitant

{2-[1-{[3,5-bis(trifluoromethyl)phenyl]methyl}-5-(pyridin-4-yl)-1*H*-1,2,3-triazol-4-yl]pyridin-3-yl}(2-chlorophenyl)methanone

tradipitant

{2-[1-{[3,5-bis(trifluorométhyl)phényl]méthyl}-5-(pyridin-4-yl)-1*H*-1,2,3-triazol-4-yl]pyridin-3-yl}(2-chlorophényl)méthanone

tradipitant

{2-[1-{[3,5-bis(trifluorometil)fenil]metil}-5-(piridin-4-il)-1*H*-1,2,3-triazol-4-il]piridin-3-il}(2-clorofenil)metanona

$C_{28}H_{16}ClF_6N_5O$



transcrocetinum

transcrocetin	*all-trans*-8,8'-diapocarotene-8,8'-dioic acid
transcrocétine	acide *tout-trans*-8,8'-diapocarotène-8,8'-dioïque
transcrocetina	ácido *todo-trans*-8,8'-diapocaroteno-8,8'-dioico

$C_{20}H_{24}O_4$



ulixertinibum

ulixertinib	4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-*N*-[(1*S*)-1-(3-chlorophenyl)-2-hydroxyethyl]-1*H*-pyrrole-2-carboxamide
ulixertinib	4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-*N*-[(1*S*)-1-(3-chlorophényl)-2-hydroxyéthyl]-1*H*-pyrrole-2-carboxamide
ulixertinib	4-{5-cloro-2-[(propan-2-il)amino]piridin-4-il}-*N*-[(1*S*)-1-(3-clorofenil)-2-hidroxietil]-1*H*-pirrol-2-carboxamida

$C_{21}H_{22}Cl_2N_4O_2$



uprosertibum

uprosertib — *N*-[(2*S*)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)furan-2-carboxamide

uprosertib — *N*-[(2*S*)-1-amino-3-(3,4-difluorophényl)propan-2-yl]-5-chloro-4-(4-chloro-1-méthyl-1*H*-pyrazol-5-yl)furan-2-carboxamide

uprosertib — *N*-[(2*S*)-1-amino-3-(3,4-difluorofenil)propan-2-il]-5-cloro-4-(4-cloro-1-metil-1*H*-pirazol-5-il)furan-2-carboxamida

$C_{18}H_{16}Cl_2F_2N_4O_2$



vanucizumabum #

vanucizumab — immunoglobulin recombined G1-kappa/lambda, anti-[*Homo sapiens* ANGPT2 (angiopoietin 2, Ang2)]/anti-*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody; gamma1 heavy chain anti-ANGPT2 (1-463) [*Homo sapiens* VH (*Homo sapiens* IGHV1-2*02 (100.00%) -(IGHD)-IGHJ3*02) [8.8.22] (1-129) -*Homo sapiens* IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -IGHG1*01 hinge-CH2-CH3-CHS (hinge 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfide with light chain anti-ANGPT2 (1'-213') [glutaminyl-prolyl-glycyl (1'-3') -*Homo sapiens* V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -linker seryl-seryl (109'-110') -*Homo sapiens* IGHG1*01 CH1-hinge (CH1 (111'-208') -hinge (1-5) (209'-213')]; gamma1 heavy chain anti-VEGFA (1-453) [humanized VH (*Homo sapiens* IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 S10>C (360), T22>W (372) (347-451), CHS (452-453)) (124-453)],(226-214')-disulfide with kappa light chain anti-VEGFA (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (242-232":245-235":365-360")-trisdisulfide

vanucizumab	immunoglobuline recombinée G1-kappa/lambda, anti-[*Homo sapiens* ANGPT2 (angiopoietine 2, Ang2)]/anti-*Homo sapiens* VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé; chaîne lourde gamma1 anti-ANGPT2 (1-463) [*Homo sapiens* VH (*Homo sapiens* IGHV1-2*02 (100.00%) -(IGHD)-IGHJ3*02) [8.8.22] (1-129) -*Homo sapiens* IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -IGHG1*01 charnière-CH2-CH3-CHS (charnière 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfure avec la chaîne légère anti-ANGPT2 (1'-213') [glutaminyl-prolyl-glycyl (1'-3') -*Homo sapiens* V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -linker séryl-séryl (109'-110') -*Homo sapiens* IGHG1*01 CH1-charnière (CH1 (111'-208') -charnière (1-5) (209'-213')]; chaîne lourde gamma1 anti-VEGFA (1-453) [VH humanisé (*Homo sapiens* IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 S10>C (360) T22>W (372) (347-451), CHS (452-453)) (124-453)],(226-214')-disulfure avec la chaîne légère kappa anti-VEGFA (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (242-232":245-235":365-360")-trisdisulfure
vanucizumab	inmunoglobulina recombinada G1-kappa/lambda, anti-[*Homo sapiens* ANGPT2 (angiopoyetina 2, Ang2)]/anti-*Homo sapiens* VEGFA (factor de crecimiento A del endotelio vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado; cadena pesada gamma1 anti-ANGPT2 (1-463) [*Homo sapiens* VH (*Homo sapiens* IGHV1-2*02 (100.00%) -(IGHD)-IGHJ3*02) [8.8.22] (1-129) -*Homo sapiens* IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -IGHG1*01 bisagra-CH2-CH3-CHS (bisagra 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfuro con la cadena ligera anti-ANGPT2 (1'-213') [glutaminil-prolil-glicil (1'-3') -*Homo sapiens* V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') –conector seril-seril (109'-110') -*Homo sapiens* IGHG1*01 CH1-bisagra (CH1 (111'-208') -bisagra (1-5) (209'-213')]; cadena pesada gamma1 anti-VEGFA (1-453) [VH humanizado (*Homo sapiens* IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 S10>C (360) T22>W (372) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa anti-VEGFA (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (242-232":245-235":365-360")-trisdisulfuro

anti- ANGPT2 Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW  50
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSP 100
NPYYYDSSGY YYPGAFDIWG QGTMVTVSSA SVAAPSVFIF PPSDEQLKSG 150
TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST 200
LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGECDKTH TCPPCPAPEL 250
LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV 300
HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 350
TISKAKGQPR EPQVCTLPPS RDELTKNQVS LSCAVKGFYP SDIAVEWESN 400
GQPENNYKTT PPVLDSDGSF FLVSKLTVDK SRWQQGNVFS CSVMHEALHN 450
HYTQKSLSLS PGK                                         463
```

anti- ANGPT2 Light chain / Chaîne légère / Cadena ligera

```
QPGLTQPPSV SVAPGQTARI TCGGNNIGSK SVHWYQQKPG QAPVLVVYDD  50
SDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DSSSDHYVFG 100
TGTKVTVLSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS 150
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS 200
NTKVDKKVEP KSC                                         213
```

anti-VEGFA Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW  50
INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP 100
HYYGSSHWYF DVWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPC RDELTKNQVS LWCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                    453
```

anti-VEGFA Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF  50
TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 156-216 277-337 383-441
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L (C23-C104) 22'-87' 137'-193'
23'"-88'" 134'"-194'"
Inter-H-L 236-213' 226"-214'"
Inter-H-H 242-232" 245-235" 365-360"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
313, 303"

varlilumabum #

varlilumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* anti-CD27 (TNFRSF7, tumor necrosis factor receptor superfamily member 7)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-452)[*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12](1-119) -IGHG1*01 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (120-449) -glycyl-seryl-seryl (450-452)],(222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (228-228":231-231")-bisdisulfide

varlilumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* anti-CD27 (TNFRSF7, membre 7 de la superfamille des récepteurs du facteur de nécrose tumorale)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-452)[*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12](1-119) -IGHG1*01 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (120-449) -glycyl-séryl-séryl (450-452)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

varlilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* anti-CD27 (TNFRSF7, miembro 7 de la superfamilia de receptores del factor de necrosis tumoral)] anticuerpo monoclonal de *Homo sapiens;*
cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (120-449) -glicil-seril-seril (450-452)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYDMHWVRQA PGKGLEWVAV  50
IWYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGS 100
GNWGFFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGKG 450
SS                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIS RWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNTYPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22''-96''	146''-202''	263''-323''	369''-427''
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	222-214'	222''-214'''		
Inter-H-H (h 11, h 14)	228-228''	231-231''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299''

velpatasvirum

velpatasvir

methyl {(2*S*)-1-[(2*S*,5*S*)-2-(9-{2-[(2*S*,4*S*)-1-{(2*R*)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1*H*-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-*d*]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate

velpatasvir

{(2*S*)-1-[(2*S*,5*S*)-2-(9-{2-[(2*S*,4*S*)-1-{(2*R*)-2-[(méthoxycarbonyl)amino]-2-phénylacétyl}-4-(méthoxyméthyl)pyrrolidin-2-yl]-1*H*-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-*d*]imidazol-2-yl)-5-méthylpyrrolidin-1-yl]-3-méthyl-1-oxobutan-2-yl}carbamate de méthyle

velpatasvir

{(2*S*)-1-[(2*S*,5*S*)-2-(9-{2-[(2*S*,4*S*)-1-{(2*R*)-2-[(metoxicarbonil)amino]-2-fenilacetil}-4-(metoximetil)pirrolidin-2-il]-1*H*-imidazol-4-il}-1,11-dihidro[2]benzopirano[4',3':6,7]nafto[1,2-*d*]imidazol-2-il)-5-metilpirrolidin-1-il]-3-metil-1-oxobutan-2-il}carbamato de metilo

$C_{49}H_{54}N_8O_8$



venetoclaxum

venetoclax	4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-*N*-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide
vénétoclax	4-(4-{[2-(4-chlorophényl)-4,4-diméthylcyclohex-1-én-1-yl]méthyl}pipérazin-1-yl)-*N*-[(3-nitro-4-{[(oxan-4-yl)méthyl]amino}phényl)sulfonyl]-2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide
venetoclax	4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-*N*-[(3-nitro-4-{[(oxan-4-il)metil]amino}fenil)sulfonil]-2-[(1*H*-pirrolo[2,3-*b*]piridin-5-il)oxi]benzamida

$C_{45}H_{50}ClN_7O_7S$



verinuradum

verinurad	2-{[3-(4-cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl}-2-methylpropanoic acid
vérinurad	acide 2-{[3-(4-cyanonaphtalén-1-yl)pyridin-4-yl]sulfanyl}-2-méthylpropanoïque
verinurad	ácido 2-{[3-(4-cianonaftalen-1-il)piridin-4-il]sulfanil}-2-metilpropanoico

$C_{20}H_{16}N_2O_2S$



vonapanitasum

vonapanitase — recombinant DNA derived type I pancreatic elastase, produced in *Pichia pastoris*: [26-tryptophan(Arg>Trp),202-leucine(Val>Leu),225-arginine(Gln>Arg)]mature human CELA1 (chymotrypsin-like elastase family member 1, pancreatic elastase 1, elastase 1, EC 3.4.21.36) non-glycosylated

vonapanitase — élastase pancréatique de type I, produite à partir d'ADN recombinant, produite par *Pichia pastoris*: [26-tryptophane(Arg>Trp),202-leucine(Val>Leu),225-arginine(Gln>Arg)]CELA1 humaine à maturité (membre 1 de la famille des élastases analogues de la chymotrypsine, élastase 1 pancréatique, élastase 1, EC 3.4.21.36) non-glycosylée

vonapanitasa — elastasa pancreática de tipo I, producida a partir de ADN recombinante, producida por *Pichia pastoris*: [26-triptófano(Arg>Trp),202-leucina(Val>Leu),225-arginina(Gln>Arg)]CELA1 humana madura (miembro 1 de la familia de elastasas análogas a la quimotripsina, elastasa 1 pancreática, elastasa 1, EC 3.4.21.36) no glicosilada

Sequence / Séquence / Secuencia

```
VVGGTEAGRN SWPSQISLQY RSGGSWYHTC GGTLIRQNWV MTAAHCVDYQ 50
KTFRVVAGDH NLSQNDGTEQ YVSVQKIVVH PYWNSDNVAA GYDIALLRLA 100
QSVTLNSYVQ LGVLPQEGAI LANNSPCYIT GWGKTKTNGQ LAQTLQQAYL 150
PSVDYAICSS SSYWGSTVKN TMVCAGGDGV RSGCQGDSGG PLHCLVNGKY 200
SLHGVTSFVS SRGCNVSRKP TVFTRVSAYI SWINNVIASN            240
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
30-46 127-194 158-174 184-214

vorhyaluronidasum alfa #

vorhyaluronidase alfa — human hyaluronidase PH-20 (hyaluronoglucosaminidase PH-20, sperm adhesion molecule 1, EC 3.2.1.35) precursor-(36-482)-peptide (mature-(1-447)-peptide), produced in Chinese hamster ovary (CHO) DG44dhfr- cells, glycoform alfa

vorhyaluronidase alfa — hyaluronidase PH-20 humaine (hyaluronoglucosaminidase PH-20, molécule adhésive 1 du sperme, EC 3.2.1.35) précurseur-(36-482)-peptide (à maturité-(1-447)-peptide), produite par des cellules ovariennes de hamster chinois DG44dhfr-, forme glycosylée alfa

vorhialuronidasa alfa

hialuronidasa PH-20 humana (hialuronoglucosaminidasa PH-20, molécula de adhesión 1 de esperma, EC 3.2.1.35) precursor-(36-482)-péptido (maduro-(1-447)-péptido), producida por células ováricas de hamster chino DG44dhfr-, forma glicosilada alfa

$C_{2327}H_{3553}N_{589}O_{667}S_{20}$ (protein)

Sequence / Séquence / Secuencia

```
LNFRAPPVIP NVPFLWAWNA PSEFCLGKFD EPLDMSLFSF IGSPRINATG 50
QGVTIFYVDR LGYYPYIDSI TGVTVNGGIP QKISLQDHLD KAKKDITFYM 100
PVDNLGMAVI DWEEWRPTWA RNWKPKDVYK NRSIELVQQQ NVQLSLTEAT 150
EKAKQEFEKA GKDFLVETIK LGKLLRPNHL WGYYLFPDCY NHHYKKPGYN 200
GSCFNVEIKR NDDLSWLWNE STALYPSIYL NTQQSPVAAT LYVRNRVREA 250
IRVSKIPDAK SPLPVFAYTR IVFTDQVLKF LSQDELVYTF GETVALGASG 300
IVIWGTLSIM RSMKSCLLLD NYMETILNPY IINVTLAAKM CSQVLCQEQG 350
VCIRKNWNSS DYLHLNPDNF AIQLEKGGKF TVRGKPTLED LEQFSEKFYC 400
SCYSTLSCKE KADVKDTDAV DVCIADGVCI DAFLKPPMET EEPQIFY    447
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
25-316 189-203 341-352 346-400 402-408 423-429

Glycosylation sites (N, T) / Sites de glycosylation (N, T) / Posiciones de glicosilación (N, T)
Asn-47 Asn-131 Asn-200 Asn-219 Asn-333 Asn-358 Thr-440

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 57
Dénominations communes internationales proposées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 60 **beroctocogum alfa #**

beroctocog alfa *replace the description by the following one*
béroctocog alfa *remplacer la description par la suivante*
beroctocog alfa *sustitúyase la descripción por la siguiente*

human blood-coagulation factor VIII-(1-741)-peptide complex with human blood-coagulation factor VIII-(1649-2332)-peptide

combinaison du facteur VIII de coagulation humain-(1-741)-peptide avec le facteur VIII de coagulation humain-(1649-2332)-peptide

combinación del factor VIII de coagulación humano-(1-741)-péptido con el factor VIII de coagulación humano-(1649-2332)-péptido

Recommended International Non Proprietary Names (Rec. INN): List 59
Dénominations communes internationales proposées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 74 & 75 **beroctocogum alfa #**

beroctocog alfa *replace the structure by the following one*
béroctocog alfa *remplacer la structure par la suivante*
beroctocog alfa *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR S          741
```

Light chain / Chaîne légère / Cadena ligera

```
                                                    EI 1650
TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700
AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750
ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000
LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050
ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100
FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300
LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY                   2332
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Modified residues / Résidus modifiés / Restos modificados

Y
346-718-719-723-1664-1680
O-sulfoTyr



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-1810 Asn-2118

delete/supprimer/suprimáse

$C_{3821}H_{5813}N_{1003}O_{1139}S_{35} + C_{3547}H_{5400}N_{956}O_{1033}S_{35}$

Recommended International Non Proprietary Names (Rec. INN): List 71
Dénominations communes internationales proposées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

p. 96 **ombitasvirum**

ombitasvir replace the chemical name by the following one
ombitasvir remplacer le nom chimique par le suivant
ombitasvir sustitúyase el nombre químico por el siguiente

dimethyl *N*,*N*'-([(2*S*,5*S*)-1-(4-*tert*-butylphenyl)pyrrolidine-2,5-diyl]bis{4,1-phenyleneazanediylcarbonyl[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate

N,*N*'-([(2*S*,5*S*)-1-(4-*tert*-butylphényl)pyrrolidine-2,5-diyl]bis{4,1-phénylèneazanediylcarbonyl[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})biscarbamate de diméthyle

N,*N*'-([(2*S*,5*S*)-1-(4-*terc*-butilfenil)pirrolidina-2,5-diil]bis{4,1-fenilenoazanodiilcarbonil[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})biscarbamato de dimetilo

p. 98 & 99 **paclitaxelum trevatidum**

paclitaxel trevatide
paclitaxel trévatide
paclitaxel trevatida

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

short modified fragment of human amyloid beta A4 protein covalently linked to three molecules of paclitaxel through succinyl linkers:
$N^{2.1}$,$N^{6.10}$,$N^{6.15}$-tris(4-{[(1*S*,2*R*)-1-benzamido-3-{[4,10β-bis(acetyloxy)-2α-(benzoyloxy)-5β,20-epoxy-1,7β-dihydroxy-9-oxotax-11-en-13α-yl]oxy}-3-oxo-1-phenylpropan-2-yl]oxy}-4-oxobutanoyl) ([318-L-threonine(P>T1),324-L-serine(C>S7),325-L-arginine(G>R8),327-L-lysine(N>K10),332-L-lysine(D>K15)] human amyloid beta A4 protein precursor-(318-336)-peptide)

fragment court et modifié de la protéine bêta A4 amyloïde humaine lié de façon covalente à trois molécules de paclitaxel par autant de succinyles :
$N^{2.1}$,$N^{6.10}$,$N^{6.15}$-tris(4-{[(1*S*,2*R*)-1-benzamido-3-{[4,10β-bis(acétyloxy)-2α-(benzoyloxy)-5β,20-époxy-1,7β-dihydroxy-9-oxotax-11-en-13α-yl]oxy}-3-oxo-1-phénylpropan-2-yl]oxy}-4-oxobutanoyl) ([318-L-thréonine(P>T1),324-L-sérine(C>S7),325-L-arginine(G>R8),327-L-lysine(N>K10),332-L-lysine(D>K15)] précurseur de la protéine amyloïde bêta A4 humaine-(318-336)-peptide)

fragmento corto y modificado de la proteína beta A4 amiloide humana unido covalentemente a tres moléculas de paclitaxel mediante succinilos :
$N^{2.1}$,$N^{6.10}$,$N^{6.15}$-tris(4-{[(1*S*,2*R*)-1-benzamido-3-{[4,10β-bis(acetiloxi)-2α-(benzoiloxi)-5β,20-epoxi-1,7β-dihidroxi-9-oxotax-11-en-13α-il]oxi}-3-oxo-1-fenilpropan-2-il]oxi}-4-oxobutanoil) ([318-L-treonina(P>T1),324-L-serina(C>S7),325-L-arginina(G>R8),327-L-lisina(N>K10),332-L-lisina(D>K15)] precursor de la proteína amiloide beta A4 humana-(318-336)-péptido

p. 115 **vedroprevirum**

vedroprevir
védroprévir
vedroprevir

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

(1*R*,2*R*)-1-{(2*S*,4*R*)-1-{(2*S*)-2-[({[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy}carbonyl)amino]-3,3-dimethylbutanoyl}-4-[(8-chloro-7-[2-(morpholin-4-yl)ethoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]pyrrolidine-2-carboxamido}-2-ethylcyclopropane-1-carboxylic acid

acide (1*R*,2*R*)-1-{(2*S*,4*R*)-1-{(2*S*)-2-[({[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy}carbonyl)amino]-3,3-diméthylbutanoyl}-4-[(8-chloro-7-[2-(morpholin-4-yl)éthoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl}quinoléin-4-yl)oxy]pyrrolidine-2-carboxamido}-2-éthylcyclopropane-1-carboxylique

ácido (1*R*,2*R*)-1-{(2*S*,4*R*)-1-{(2*S*)-2-[({[(1*R*,3*r*,5*S*)-biciclo[3.1.0]hexan-3-il]oxi}carbonil)amino]-3,3-dimetilbutanoil}-4-[(8-cloro-7-[2-(morfolin-4-il)etoxi]-2-{2-[(propan-2-il)amino]-1,3-tiazol-4-il}quinolin-4-il)oxi]pirrolidina-2-carboxamido}-2-etilciclopropano-1-carboxílico

Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.